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ABSTRACT 
 
 Presenilin-1 (PS-1) is the catalytic core of the γ-secretase complex, which is best 
known for its role in the generation of the Alzheimer disease (AD)-related β-amyloid 
peptide. Mutated forms of PS-1 are known to be associated with particularly aggressive 
forms of AD. Changes in monoaminergic neurotransmitter systems, including the 
serotonin and norepinephrine systems, have long been associated with some of the 
earliest events in AD, whereas changes in the availability of these same monoamines 
have historically been associated with clinical depression. Therefore, it is not surprising 
that depression has now been proposed as a risk factor for developing AD and that pre-
demented carriers of mutated forms of PS-1 are more prone to developing depression. 
The enzyme monoamine oxidase-A (MAO-A) is historically associated with depression 
and is also a known risk factor for AD. Given this, I hypothesized that MAO-A 
represents a neurochemical link between depression and AD, and I chose to examine the 
influence of PS-1 mutations on MAO-A function in vivo/ex vivo and in vitro. 
 I first focused on the PS-1(M146V) knock-in mouse model of AD-related PS-1/γ-
secretase function. I used a radioenzymatic assay to estimate MAO-A catalytic activity 
and immunoblot analysis to determine MAO-A protein expression, and found that MAO-
A activity does not correlate with MAO-A expression in the cortex and cerebellum of the 
PS-1(M146V) mice. Furthermore, the potency of the MAO-A inhibitor clorgyline (CLG) 
is greater in both the cortex and cerebellum of the PS-1(M146V) mice compared to the 
potency of CLG in wildtype littermates. CLG dose-response curves suggest that there 
might be a change in cooperativity in the MAO-A protein from PS-1(M146V) cortex 
(which would suggest a change in conformation and/or access of the substrate to the 
catalytic pocket in MAO-A). High-pressure liquid chromatography was used to analyze 
monoamine levels in these same regions. The metabolic profile of monoamines (i.e. 
serotonin, dopamine and norepinephrine) suggests that PS-1(M146V) inhibits MAO-A 
function in the cortex, but not in the cerebellum. Furthermore, CLG has no significant 
effect on amine levels in cortex, but tends to increase their accumulation in cerebellum. 
The overexpression of PS-1(M146V) in neuronal cultures reveals that this protein 
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affects MAO-A activity and, more importantly, that PS-1(M146V) co-precipitates with 
MAO-A, thus suggesting a possibility for a direct protein-protein interaction. This is 
supported by the observation that MAO-A activity is increased in cell extracts incubated 
with the PS-1 substrate-competitor, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT). Preliminary studies have been undertaken to identify 
the motif in MAO-A that could be acting as a binding site/target site for PS-1. 
These combined results support the hypothesis that PS-1 proteins can influence 
MAO-A function and, thus, could represent a neurochemical link between depression and 
AD. Furthermore, MAO-A appears to be a novel interactor for PS-1/γ-secretase. This 
could well explain some of the ambiguous literature associated with both of these 
proteins in disorders as diverse as depression and AD. 
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1. General Introduction. 
1.1 Major Depressive Disorder. 
1.1.1 History.  
 As early as the 17th century, major depression was recognized and known as 
melancholia, a condition thought to be due to the change of dominant humor in an 
individual. It was not until the early 19th century that the Swiss psychiatrist Adolf Meyer 
presented the term ‘depression’. He also described a framework that contained both 
social and biological aspects to emphasize the environment of a person’s life [1, 2]. The 
first person that associated depression with psychiatric symptoms (in 1865) was Louis 
Delasiauve, a psychiatrist from France. Around this time, depression was being 
associated with a low level of physiological emotional function [3] and this new 
‘condition’ was more associated with women [4]. In the middle of the 20th century, 
researchers observed that an imbalance of monoamine neurotransmitter in the brain could 
be induced pharmacologically with compounds such as reserpine, and that this induced 
depressive symptoms [5]. At the same time, the term Major Depressive Disorder was 
introduced. 
 
1.1.2 Symptoms and development of depression. 
 Major Depressive Disorder is a mental disorder that adversely affects the patient’s 
family, general health, normal life, including working, sleeping, eating habits and also 
personal relationships [6]. Depression affects people of all races and does not 
discriminate between male and female, although females do tend to suffer from 
depression more than men [7]. In 2009, approximately 9.5% of the population in 
America, aged 18 and older, suffered from depression, and around 3.4% of this 
population had suicidal tendencies. Symptoms of depression also include loss of interest 
in normal activities, low self-esteem, poor memory and problems with concentration [8]. 
Cognitive symptoms [8] and obvious slowing movements [9] are usually common with 
older depressed people. In severe cases, the patient may also display symptoms of 
psychosis, such as delusions and hallucinations, but this is less common [10]. Compared 
with the aged population, depressed children may show varying symptoms depending on 
their age [1], and can often display aggression or irritability rather than a low mood [6]. 
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This might explain, in part, why diagnosis could be missed or delayed in children. As 
stated above, women tend to experience depression more often than men (almost twice as 
often) [7] and the pattern of symptoms often differs between these two populations, in 
part due to differences in hormones [11] and the ability to respond to social pressures.  
 
1.1.3 Monoamine-Deficiency hypothesis of depression. 
 Genetics suggest that complex features, rather than a single gene, are involved in 
major depression. Serotonin (5-HT)-transporter-linked polymorphic region is a target 
region that affects transcription of the 5-HT transporter gene. One polymorphism causes 
the ‘short’ allele, decreases transcription efficiency and results in a decreased expression 
of the 5-HT transporter. The result is decreased uptake of 5-HT into the presynaptic cells 
[12, 13] and a potential contribution to depression [14]. Aside from the 5-HT-transporter-
linked polymorphic region, no strongly-correlated, specific risk factor for depression has 
been identified [15]. However, the genome related to a predisposition to depression could 
be affected epigenetically by environmental factors. For example, Weaver reported that 
an increase in maternal care by rat dams altered the promoter of the glucocorticoid 
receptor gene, and this altered the stress responses of their offspring [16]. 
 The monoamine theory of depression is widely accepted as the neurobiological 
basis for major depression. As early as the 1960s, it was believed that depression was 
associated with generally low levels of several neurotransmitters, such as serotonin, 
norepinephrine and dopamine [17, 18]. Blocking monoamine oxidase was one of the first 
biological mechanisms associated with antidepressant properties and, not surprisingly, 
the first-generation antidepressants, the tricyclic antidepressants, inhibited the reuptake of 
these neurotransmitters. Therefore, a deficiency of brain monoaminergic tone clearly 
plays a critical role in inducing Major Depressive Disorder. This mental disorder could be 
reversed by agents that increase the availability of brain monoamines [18]. Such agents 
function by blocking inhibitory presynaptic neuronal metabolism, inhibiting the reuptake 
of monoamines from the synapse and/or reducing monoamine intraneuronal metabolism 
[19, 20]. So far, most of the studies related to major depression have been concentrating 
on the low density of presynaptic monoamine transporter. Apart from this theory, it is 
also observed that an elevated brain monoamine oxidase-A level can increase the 
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metabolism of monoamines, which would clearly support why monoamines are usually 
low in depressed subjects [21]. Among the publications related to monoamine oxidase-A, 
more tend to focus on the high activity-related allele of the gene for monoamine oxidase-
A rather than the protein itself. Theoretically, a higher activity of the monoamine 
oxidase-A protein could elevate the metabolism of monoamines, such as 5-HT, NE and 
DA, in much the same way as an increase in the expression of the MAO-A protein would. 
 
1.2 Monoamine oxidase-A (MAO-A). 
1.2.1 Classification of MAO isoforms. 
 Monoamine oxidase is a flavin adenine dinucleotide domain-containing enzyme 
that is expressed predominantly on the outer membrane of the mitochondria and is widely 
distributed in all organisms [22]. MAOs catalyze the deamination of monoamines, thus 
generating aldehydes, and generating reaction byproducts such as hydrogen peroxide and 
ammonia. Reactive oxygen species can be produced from hydrogen peroxide and can 
induce damage to the mitochondria and trigger neuronal cell apoptosis [23].  
 In mammals, two isoforms of MAO are expressed. These isoforms, MAO-A and 
MAO-B, share approximately 70% identity of primary amino acid sequences [24, 25] and 
are generally detected, to varying degrees, in most organs [26]. MAO-A is very highly 
expressed in placenta while MAO-B is the predominant isoform in platelets and 
lymphocytes [27]. Their distribution also differs in the brain. MAO-A is more abundant 
in catecholaminergic neurons, while MAO-B is found more often in glial cells as well as 
in serotonergic and histaminergic neurons [28-30]. Before their molecular 
characterization, MAOs were often distinguished based on their substrate and inhibitor 
sensitivity. To some degree, there are overlaps of enzymatic actions for the two isoforms. 
In most species, they both present a good affinity for dopamine (DA), tryptamine, etc 
[31]. In rodent brain, MAO-A is the main enzyme for DA degradation, while in human 
brain, MAO-B is the main enzyme for DA oxidation [32]. Generally, MAO-A has a high 
affinity for serotonin (5-HT) and norepinephrine (NE), whereas MAO-B prefers β-
phenylethylamine (PEA) [33]. Therefore, in most cases, 5-HT levels can be enhanced by 
inhibition of MAO-A, but not MAO-B. However, exceptions to this rule could happen, 
for example, depending on the change of substrate/enzyme concentration (i.e. the 
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respective isoforms will oxidize the other’s substrate if enough of the substrate is 
available or if the particular isoform is not expressed at sufficiently high levels) [34]. 
 The two isoenzymes can also be characterized pharmacologically. MAO-A is 
sensitive to the selective inhibitor clorgyline [35], while MAO-B is blocked by low 
concentration of L-deprenyl [36]. Recently, many researchers have focused on 
developing different types of MAO inhibitors and have put effort into studying their 
pharmaceutical effects in mental disorders, such as depression and Alzheimer’s disease. 
This will be discussed in the following sections. 
 
1.2.2 MAO-A structure. 
 The primary amino acid sequence of MAO-A is highly important for its catalytic 
activity. In the molecule, there is a conservative sequence consisting of Ser-Gly-Gly-Cys-
Tyr, which binds the flavin adenine dinucleotide cofactor [37], and mutagenesis studies 
have shown that amino acids 152-366 are critical for inhibitor and substrate binding [38, 
39]. The 3D-structure of MAO-A has been studied and modeled in recent years [40, 41] 
(Figure 1.1). Edmondson’s research group provided a nice representation of the three 
dimensional structure of MAO-A [42]. They also compared structures of human MAO-A 
(hMAO-A) and rat MAO-A (rMAO-A). Although the primary sequence of hMAO is 
quite similar to that of the rat, their catalytic sites differ. Crystallography suggests that, 
unlike the dimer-form of rMAO-A and hMAO-B, hMAO-A’s active domain contains a 
single hydrophobic cavity-shaping loop (residues 210-216), which has a larger volume 
than rMAO-A’s, and, in contrast to rMAO-A, hMAO-A works as a monomer [42]. The 
conformation of the cavity is controlled by the formation of dimer in rMAO-A. 
Therefore, despite hMAO-A and rMAO-A having 92% sequence identity, hMAO-A 
exhibits a 10-times lower affinity for its selective inhibitor clorgyline than does rMAO-A 
[39]. 
 
1.2.3 Physiological functions of MAO-A.  
 The physiological functions of MAO-A are slightly different in peripheral tissues 
than in the brain. In tissues such as liver and lungs, MAO-A exerts protective effects by 
removing dietary amines from the blood [43]. In the central nervous system, MAO-A is 
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important in monoamine neurotransmitter metabolism in the nerve terminals, and also in 
preventing excessive release of these neurotransmitters from the glial cells. It is known 
that serotonergic neurons have a relatively low expression of MAO-A, but high 
expression of MAO-B. This indicated that glial cells could play a very important role in 
degrading 5-HT. Indeed, only inhibition of MAO-A, but not MAO-B, can dramatically 
increase the levels of 5-HT and also exert antidepressant effects [43]. MAO-B in the 
neurons might only target foreign amines and, thus, limit their entry into synaptic 
vesicles.   
 MAO-A has been linked with aggressive behaviour [44]. Indeed, disruption of the 
mao-A gene by insertional mutagenesis in a mouse model results in a dramatic increase of 
5-HT and NE, but only a modest elevation of DA. Not surprisingly, loss of MAO-A in 
this mouse strain leads to aggressive behaviour [44, 45], which resembles the aggressive 
phenotype seen in a human kindred with a deletion in the MAO-A gene (affected males 
exhibit borderline intelligence and pathologic impulsive aggression) [46, 47]. MAO-A 
knock-out mice also appear to have a better fear-related memory [48, 49], whereas MAO-
A deficiency in rodent usually induces an enhanced resistance to environmental stress 
[44]. 
 
1.2.4 MAO-A inhibition and neurodegenerative disease. 
 MAO-A inhibitors (MAOIs) were the first developed antidepressants and are a 
class of powerful drugs to treat depressive disorder. A significant elevation of 5-HT and 
NE can be observed after MAOI treatment [50]. It has been reported that due to the 
“cheese effect” associated with these compounds (an effect due to a significant increase 
in circulating dietary tyramine (from foodstuffs such as aged cheese, hence the name, and 
wine) resulting from inhibition of gut wall MAO) [51], MAOIs should be prescribed as a 
second choice for depressed patients, only after 5-HT reuptake inhibitors have been tried. 
Recently-developed reversible MAO-A inhibitors such as moclobemide [52] and 
brofaromine [53] are particularly efficacious in refractory depression [54-56]. Studies 
have now shown that depression can promote cognitive impairment and that it is a 
potential risk factor for Alzheimer’s disease [57]. Hydrogen peroxide (H2O2), as a natural 
by-product of  MAO-mediated metabolism, can  contribute to  ROS formation and trigger 
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Figure 1.1: 3-D structure of human MAO-A with flavin adenine dinucleotide and 
clorgyline bound. The monomer is depicted using ribbons. MAO-A is attached to the 
outer membrane (depicted as a light green strip) of mitochondria (the C-terminal 
membrane region is highlighted in green and is anchored to the membrane).  The flavin 
adenine dinucleotide-binding domain is highlighted in blue. The MAO-A inhibitor 
clorgyline is located in the very center of the structure and is represented by the green, 
black and white spheres. (Image used with permission, from ref [42]) 
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mitochondrial damage leading to neuronal cell death [23]. Therefore, it is not surprising 
that MAO-A inhibition can also be an effective treatment in neurodegenerative diseases 
such as Parkinson disease, Huntington’s disease and Alzheimer’s disease [20]. As my 
thesis focuses MAO in Alzheimer’s disease, the literature review will focus more on 
Alzheimer’s disease. 
 
1.3 Alzheimer's disease. 
1.3.1 Classification and pathophysiology. 
Alzheimer’s disease (AD) is named for  the German psychiatrist who first described 
the disease and its neuropathology in 1906. It is now recognized as one of the most 
prevalent neurodegenerative diseases related to aging with an incidence of approximately 
5%-10% of the population above 65 years of age [58]. The pathological changes include 
neuronal degeneration (most obvious in cerebral cortex and hippocampus), the 
intracellular neurofibrillary tangle (NFT) and the extracellular senile plaque [59]. 
Memory loss and dementia are two manifestations in the disease. Phosphorylation of the 
Tau protein is key to NFT formation while aggregated β-amyloid peptide (Aβ) is the 
central component of senile plaque [59]. Deposition of Aβ leads to oxidative stress, 
apoptosis, or abnormal growth of axon as well as enhancing NFT formation [60]. 
Types of AD include late-onset (also named sporadic AD) and early-onset (or 
familial) AD (FAD). Late-onset AD is the most common form of the disease. The 
likelihood for people getting the disease doubles every 5 years after the age of 65 and 
affects more than 30% of people aged 85 and over [58]. The early-onset form of the 
disease is less common then sporadic AD and often affects less than 10% of AD patients. 
Early-onset AD is mainly associated with three mutant genes, presenilin-1 (PS-1), 
presenilin-2 (PS-2) and amyloid protein precursor (APP). In some extremely aggressive 
cases of FAD, people may develop AD in their late 20s and early 30s [61]. 
 
1.3.2 The Amyloid hypothesis of AD. 
 Deposition of Aβ in the wall of cerebral blood vessels is the most important 
feature of AD. The Aβ peptide can contain between 39 to 43 amino acids and is 
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generated from the cleavage product of transmembrane APP [62]. APP is expressed in all 
types of cells and although the function of APP in peripheral system remains unclear, it 
has been associated with synapse formation as well as neuronal migration in the brain 
[63, 64]. Three enzymes, α-, β-, and γ-secretase are involved in two pathways associated 
with the APP cleavage process (Figure 1.2). In the ‘non-amyloidogenic’ pathway, APP is 
first cleaved by α-secretase between residues 16 and 17 of the Aβ peptide; this 
effectively inhibits Aβ formation and releases the soluble α-site cleavage product sAPPα 
[65].  Mutations in the APP protein that have been associated with AD often are localized 
near the β-secretase site and facilitate the cleavage by β-secretase and the release of the 
Aβ peptide. β-secretase cleaves APP between residues 596 and 597, thus producing the 
C-terminus of  APP, referred to as C99 [66]. The membrane-bound C99 fragment is 
further cleaved by γ-secretase between residues 637 and 639 to release the full length Aβ 
peptide [67]. Different lengths of Aβ monomers can be produced following the 
proteolytic processing because γ-secretase is able to cut APP at different sites. However, 
39-42-mers of Aβ appear to be the major forms of Aβ in plaques in the brain of AD 
patients [68]. 
 
1.4 The γ-secretase complex. 
1.4.1 An introduction to γ-secretase. 
The intramembrane proteolysis of Type I transmembrane proteins by the γ-
secretase complex is an evolutionarily conserved biochemical process in most mammals 
[69]. Four components have been identified in this membrane-bound complex; these are 
presenilin, nicastrin, APH-1 and PEN-2 [70]. Researchers first recognized γ-secretase 
because of its intramembrane-cleaving function during the processing of Aβ in AD [60]. 
As mentioned above, γ-secretase acts as a key enzyme during the cleavage of APP and 
produces Aβ-40/42-mers. In addition to its role in AD, during nervous system 
development and neuronal outgrowth, γ-secretase also serves as an important mediator in 
the Notch signaling pathway [71]. Following cleavage by γ-secretase, the intracellular 
domain of the Notch receptor is released from the cell membrane and translocates to the 
nucleus, where it regulates a number of genes [72, 73]. Therefore, γ-secretase normally 
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plays a crucial role in diverse signal transduction events. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The amyloid precursor protein (APP) is proteolytically processed by 
multiple cleavage events. APP is cleaved by the β- and γ-secretase enzyme complexes 
sequentially to release the Aβ(1-40) and/or Aβ(1-42) fragments. These fragments are 
thought to contribute to the pathological progression of AD. Under non-pathological 
conditions, APP is cleaved by α-secretase or BACE-2 (β-site APP-cleaving enzyme 2), 
thus precluding the release of the amyloidogenic and toxic Aβ fragment. (Image used 
with permission, from ref [74]) 
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Presenilin-1 (PS) is known as the central catalytic component of the γ-secretase 
complex [59]. PS is an eight-domain transmembrane protein and it is endoproteolytically 
cleaved within the cytoplasmic loop to generate an N-terminal fragment (NTF) and a 
smaller C-terminal fragment (CTF) [75]. These two fragments of PS-1 remain associated 
in vivo and it is this heterodimeric conformation that mediates γ-secretase's catalytic 
activity [75]. PS-1 is now well known to be involved in both normal and abnormal 
biological processes. The γ-secretase activity can be interfered by several substitutions 
within the PS protein, i.e. aspartate 257 (D257) or by the deletion of exon9 in PS-1 (the 
deletion of exon 9 precludes the endoproteolytic processing of the PS-1 protein) [76, 77]. 
The aspartate 257 (D257) and D385 residues are very important for the function of the 
complex and are central to substrate recognition. Although PS-1 is indispensable to the 
function of the γ-secretase complex, overexpressing PS-1 alone does not increase γ-
secretase activity [73], which suggests that the function of PS-1 and its expression level 
are tightly controlled by other co-factors. Recent research indicates that nicastrin is one of 
the potential limiting factors for γ-secretase activity, and nicastrin exerts its influence by 
associating directly with PS-1 [78]. However, co-expression studies quickly revealed that 
γ-secretase function is not solely dependent on these two proteins [79], and two other 
proteins identified as APH-1 and PEN-2 are now known to be essential factors for PS-1 
endoproteolysis and for γ-secretase activity [73].  
 
1.4.2 Subcellular localization of the PS-1 protein.   
 PS-1/γ-secretase is expressed widely on numerous cellular organelles, including 
the endoplasmic reticulum (ER), the plasma membrane, the nuclear envelope, and 
lysosomal membranes [80-82]. PS-1 has been detected in the Golgi complex [83, 84], but 
whether PS-1 exists on the Golgi membrane is still under dispute.  
 Recently, a group from Sweden reported, based on their immunoelectron 
microscopy study and subcellular analysis, that active PS-1 also localizes to the 
mitochondrial membranes [85, 86]. Although the function of PS-1/γ-secretase in 
mitochondria is unknown, this does open up the intriguing possibility that PS-1 is 
exerting effects on an organelle that is not its usual location within the cell, i.e. the 
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endoplasmic reticulum. Knowing the subcellular localization of PS-1 will help to 
understand more about the function of this enzyme complex function and about its 
interaction with other proteins. More recently, Area-Gomez and colleagues reported that 
presenilins are enriched in endoplasmic reticulum membranes, particularly the portion of 
the membrane that is in close proximity to mitochondria [86]. Thus, a biochemical link as 
well as a physical link allows for protein-protein interactions between the endoplasmic 
reticulum and mitochondria, which in turn allows for inter-organelle communication and 
protein trafficking [87].  
 
1.4.3 γ-Secretase signalling. 
 Two evolutionally conserved aspartate residues, D257 and D385 (located on PS-
1), play a crucial role in γ-secretase function [77]. Currently, APP and Notch are the two 
best known substrates to have been associated with γ-secretase cleavage. Processing of 
APP was described above. The Notch signaling pathway is involved with cell fate 
decision during both embryonic and adult life, and reduction of Notch signaling can be 
observed in PS-1 knock-out animals [74]. The Notch pathway is highly conserved across 
most multi-cellular organisms [88] and Notch undergoes a similar cleavage process as 
described above for APP (Figure 1.3). The transduction pathway includes three 
components: ligand, intracellular Notch receptor and transcription factors [89]. The notch 
gene family encodes different types of Notch receptors, which interact mainly with five 
ligands (JAG1, JAG2, and three Delta-like ligands) [90]. Following the interaction with 
ligands on the plasma membrane, Notch is cleaved by the ADAM (a distintegrin and 
metalloprotease) family of metalloproteases [88] and the membrane-bound fragment can 
subsequently be cleaved by PS-1/γ-secretase. The resulting fragment, termed the Notch 
intracellular domain (NICD), can translocate to the nucleus (in much the same way as the 
analogous APP fragment can, as discussed above) and target transcriptional factors such 
as CSL [91]. Binding with Notch, CSL can convert from transcriptional suppressor to an 
activator, and then induce a series of downstream events. Presenilins are required for both 
APP and Notch proteolysis. Therefore, these two events can be both blocked by PS/γ-
secretase inhibitors. Not surprisingly, inhibition of this protease as a therapy to treat AD 
must interfere the normal Notch signaling and has not led to any significant therapeutic 
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benefit. 
 
 
 
 
 
 
 
Figure 1.3: Comparison of APP and Notch processing. The APP protein and the Notch 
receptor are cleaved by β-secretase and α-secretase respectively to give raise to different 
N-terminal fragments. Then both of the proteins are processed by γ-secretase and 
generate the intracellular C-terminal fragments. The Aβ fragment is generated at the ER 
and is secreted to the outside of the cell. The Notch receptor is processed at the plasma 
membrane; the N-terminal portion mediates cell-cell communication and the C-terminal 
fragment translocates to the nucleus. 
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1.4.4 γ-secretase and AD. 
1.4.4.1 PS-1 mutants and AD. 
The APP gene was the first factor linked to familial AD [92]. However, soon 
afterwards the demonstration of mutations in the PSEN1 gene also were shown to 
contribute to familial Alzheimer's disease (FAD) [93, 94] and now more than 160 PS-1 
mutations as well as 10 PS-2 mutations have been identified [95]. Most of these 
mutations in both of the PS homologues are localized within the transmembrane domain 
or in the large intracellular loop, which has been identified as the γ-secretase catalytic 
core (Figure 1.4) [96]. Compared with PS-2, PS-1 is much more causally linked to AD. 
PS-1 is a 467 amino acid membrane binding protein with 8 or 9 transmembrane domain 
(Figure 1.4). Genetic and functional studies of AD have revealed that PS-1 mutations and 
their effects on γ-secretase function play a central role in AD pathobiology [97]. 
Compared to the other genetic factors (APP and PSEN-2), the onset age of PS-1-linked 
FAD mutations has been observed to be the earliest, starting as early as late teens [98]. 
Therefore, mutated PS-1 and its pathological function have attracted the most attention 
to-date. Of interest to this thesis work is the fact that carriers of mutated forms of PS-1 
tend to be more prone to developing depression (well before they demonstrate any signs 
of dementia) than their non-carrier siblings [99, 100]. 
Among the many PS-1 mutations, approximately 40 of them have been associated 
with FAD/early-onset AD (age of onset: 28-60). Most of these mutations are missense 
mutations (one amino acid is substituted because of a single nucleotide difference in the 
gene) except an in-frame deletion of exon9 (ΔEx9) [95]. It has been suggested that 
expression of PS-1(ΔEx9) leads to an increasing amount of N- and C- terminal fragments 
by partially blocking the full-length PS-1 degradation [101]. A hypothesis was derived 
that the deletion of exon9, through a dominant-negative mechanism, would cause a gain 
in dysfunction rather than a simple loss of function [102]. Furthermore, the PS-1(ΔEx9) 
mutation also gives the highest level of Aβ42 [78], but the mechanism used to generate 
this Aβ peptide has yet to be determined.  
The PS-1(M146V) missense mutation is frequently studied in the laboratory. The 
age of onset of AD in carriers of this mutation is between 36-40 years of age [103]. Aside 
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from altering APP processing, this mutant can increase the proteolysis of the p75 receptor 
(which has been associated with the death of cholinergic neurons) in the pre-neuronal 
PC12 cell line, [104], whereas a PS-1(M146V) knock-in mouse displays increased 
calcium dysregulation and mitochondrial oxidative stress [105-107]. 
 
1.4.4.2 Inhibition of γ-secretase. 
 Currently, overproduction of Aβ generated through sequential cleavage by β- and 
γ-secretases provides the most compelling support for the amyloid hypothesis for AD. A 
great number of FAD mutation cases are related to the PSEN-1 gene. It is known that 
FAD shares a common disease progression with late-onset AD, therefore, PS-1 has 
become an important target for therapy in both types of AD. However, in addition to 
APP, γ-secretase is also involved with the processing of a number of other substrates 
[108]. It is unclear exactly which substrates might be altered by generalized targeting of 
PS-1; however, unwanted inhibition of the Notch signalling pathway by γ-secretase 
inhibitors is the major side effect and challenge in animal research [109]. Experimentally, 
homozygous knockout of PS-1 is embryonic-lethal in mice [109], whereas animals 
treated with γ-secretase inhibitors often die from intestinal cell hyperplasia as well as 
spleen atrophy [110]. Therefore, an APP-specific inhibitor, i.e. one that targets only APP 
processing by this enzyme complex, is needed for optimal treatment of AD.  
 The semi-peptidic DAPT [N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester] is the first γ-secretase inhibitor studied in vivo. It is reported 
that Aβ production could be dose-dependently reduced by DAPT in both plasma and 
cortex [111, 112]. However, in 17-month-old mice, DAPT can reduce Aβ, but not in the 
brain. Yet, these aged mice have shown an improvement in cognitive function [113]. 
Besides, LY-411575 [112] and LY-450139 [114] are the two other orally active 
inhibitors for blocking γ-secretase in vivo. The former was reported to reduce Aβ40/42 in 
both hippocampus and cortex, while the latter has been tested in human phase II trial 
[112]. No apparent Notch-related side effects were observed with LY-450139 [114]. 
Therefore, this suggests that this compound is possible as a therapeutic inhibitor in AD as 
it would only targeting the Aβ-related γ-secretase function.
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Figure 1.4. AD-related mutations of the transmembrane protein Presenilin 1.  
Approximately 160 mutations (red) are noted in PS-1 protein (blue circles); Two 
aspartate residues, D257 and D385, within the PS-1 protein that are integral for substrate 
recognition are highlighted in yellow. The region between transmembrane domain six 
and seven is the substrate cleavage core that is central to γ-secretase function. The 
'scissors' icons along APP (green circles) indicate sites of secretase-mediated cleavage. 
The 'scissors' icons close to the junction of Exon8 and Exon9 of PS-1 indicate where PS-
1 is endoproteolytically processed. (Image used with permission, from ref [115]) 
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1.5 The association between depression and AD. 
As early as 1996, early mood changes, including depression, had been found to be 
common in AD [2]. Neurochemical changes, particularly with monoamines such as 
serotonin and noradrenaline, have long been associated with some of the earliest events in 
AD [60]. Because the main substrate of MAO-A, i.e. serotonin/5-HT, is implicated in 
major depression, MAO-A is a critical target for the treatment of clinical depression,  and 
it is also thought to contribute to oxidative stress through the production of H2O2 as a 
natural by-product of monoamine degradation. With this in mind, perhaps it is reasonable 
that some of the most vulnerable cells in the AD brain are MAO-A-immunoreactive cells 
[116]. Furthermore, region-specific noradrenergic and serotonergic degeneration occurs 
in earlier stages of AD [117, 118] and MAO-A/MAO-B expression is highly abundant in 
these two systems of the brain. It has recently been noticed that not only MAO-A, but 
also PS-1, and all other γ-secretase components, could be detected in mitochondria [85]. 
The proximity of the endoplasmic reticulum (where γ-secretase is normally expressed) to 
the mitochondria is spatially convenient for the interaction between MAO-A and PS-1. 
Since the symptoms of AD only present many years after the cellular changes, it is 
possible that MAO-A, as a key enzyme in depression, may also mediate the early 
neurochemical changes occurring in AD. Both depression [119] and MAO-A [120-124] 
are now acknowledged risk factors for AD. 
 
1.6 Hypothesis. 
 γ-Secretase plays a key role in AD. PS-1 is the catalytic core of the γ-secretase 
complex. Mutated forms of PS-1 have been associated with particularly aggressive [i.e. 
early-onset] forms of AD and some of these mutations have also been associated with 
depression in pre-demented AD patients suggesting that depression and AD might share a 
common causative mechanism. The enzyme MAO-A is historically associated with 
depression and is also a known risk factor for AD. I propose that MAO-A is a shared 
factor in these two pathologies. 
 To better understand the function of PS-1-linked FAD mutations, this project uses 
the PS-1(M146V) knock-in mouse and uses transient expression of the PS-1(M146V) 
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protein in neuronal cells (e.g. HT-22 and N2a). The PS-1(M146V) variant is very 
aggressive and is able to cause AD at a mean of 39 years of age [125]. PS-1(M146V) 
increases the level of Aβ in transgenic mice [126]. 
 Based on the facts outlined in my review of the literature, I hypothesize that PS-1 
can regulate MAO activity and that this contributes to the neurochemical changes 
associated with AD-related pathology. In this project, the influence of PS-1(M146V) on 
MAO-A function was examined both in vivo/ex vivo and in vitro. 
 
The specific aims of this thesis were: 
a. To determine if MAO-A function is affected in PS-1(M146V) knock-in animals 
as well as in PS-1(M146V) overexpressing cells; 
b.  To determine whether there are any behavioural and MAO-A-related 
neurochemical changes in PS-1(M146V) knock-in mice; 
c.  To determine whether  pharmacological inhibition of MAO-A can exert an effect 
in a PS-1(M146V) background in vivo and in vitro; 
d. To determine whether MAO-A and PS-1 proteins interact; 
e.  And, finally, if (d) proves to be true, then identify the potential motif that could 
mediate the interaction between PS-1 and MAO-A. 
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2. Material and Methods. 
2.1 Materials. 
All materials and reagent used in the experiment below were obtained from 
commercial sources (Table 2.1). The addresses of each company are listed in Table 2.2. 
The competent cells were generated from DH5α E. coli bacterial strain (ATCC). 
They were used for plasmid transformation. Three antibodies used are listed in Table 2.3. 
 
2.1.1 Cell lines. 
Mouse hippocampal-derived HT-22 cells (provided by Dr. P. Maher, The Scripps 
Research Institute, La Jolla, CA) and murine neurobastoma cells (N2a) (ATCC) were 
used in the following experiments. The characteristics of these two cell lines allow for the 
investigation of the various aspects of MAO-A protein. Both HT-22 and N2a cells are 
neuronal cell lines.  Using of HT-22 cells allows us to study the effect of PS-1 protein on 
endogenous MAO-A function due to the high basal MAO-A activity in this cell line. In 
contrast, we used N2a cell to examine the interaction between PS-1 and overexpressed 
MAO-A, as this cell line has low MAO-A activity as well as low MAO-A protein 
expression.  
 
2.1.2 Vectors and plasmids. 
Plasmid pcDNA3.1(+) (Invitrogen) and pCMV/myc/mito were used in some of 
the experiments involving transient transfection. The Immediate-early Cytomegalovirus 
virus (CMV) promoter in the pcDNA3.1(+) plasmid vector confers a high level 
expression in a wide variety of mammalian cells. The multiple cloning site (MCS) allows 
directed insertion of cDNA and the Ampicillin antibiotic resistance gene allows for 
selection of clones (e.g. only those cells that have the plasmid, and Ampicillin resistance, 
will survive in medium to which Ampicillin has been added). pcDNA3.1(+) is useful for 
studying post-translational modification of the target protein. In this thesis, 
pCMV/myc/mito was used for subcloning all of the MAO-A substitution mutants, all of 
which are targeted (by virtue of a specific targeting sequence) to the mitochondria; this 
plasmid also has the specific MCS and Ampicillin resistance gene. 
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Reagent Company 
DH5α E. coli American Type Culture Collection 
N2a American Type Culture Collection 
pcDNA3.1(+); pCMV/myc/mito Invitrogen 
DMEM GIBCO-BRL 
FBS GIBCO-BRL 
F-12 (Kaighn’s Modification) Hyclone 
Rat-tail collagen BD-Bioscience 
Trypsin-EDTA Sigma-Aldrich 
Cell Freezing Media GIBCO-BRL 
Bacto Tryptone BD Biosciences 
Bacto Yeast Extract BD Biosciences 
MgCl2 EM Science Inc. 
Glucose BDH Inc. 
EDTA EMD Chemical Inc. 
Tris-base J. T. Baker 
NaOH EMD Chemical Inc. 
Lipofectamine 2000 Invitrogen 
OPTI-MEM GIBCO-BRL 
Protease inhibitor cocktail Sigma-Aldrich 
BCA protein assay kit Pierce 
Mercaptoethanol EM Science Inc 
Bromophenol blue Sigma-Aldrich 
Tris-HCL ICN Biomedicals 
Acrylamide Bio-rad Laboratories 
LiCl EMD Chemical Inc. 
Tris-base J.T. Baker 
Glycine MP Biomedicals 
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Nitrocellulose membrane Bio-rad Laboratories 
Quikchange® Site-Directed Mutagenesis Kit Stratagene 
Tween 20 Sigma-Aldrich 
Bovine Serum Albumin Sigma-Aldrich 
Triton-X 100 Sigma-Aldrich 
Glycerol Biomedicals 
Ethyl acetate  BDH Inc. 
DAPT Sigma-Aldrich 
ECL Amersham Biosciences 
ACS Scintillation  CocktailAmersham Biosciences 
Sepharose-A/G GE Healthcare 
DMSO EM Science Inc. 
[14C]-labeled serotonin Perkin Elmer 
 
 
Table 2.1 Reagents and commercial sources. 
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Company	   Address	  
American type culture collection	   Manassas, VA, USA 
BD biosciences	   Mississauga, ON, Canada 
BDH Inc.	   Toronto, ON, Canada 
Bio-Rad	   Hercules, CA, USA 
Cell Signaling Technology	   Danvers, MA, USA 
EM Science Inc.	   Gibbstown, NJ, USA 
EMD Biosciences Inc.	   San Diego, CA, USA 
EMD Chemicals Inc.	   Gibbstown, NJ, USA 
Fermentas Inc	   Burlington, ON, Canada 
GE Healthcare	   Uppsala, Sweden 
GIBCO-BRL	   Gaithersburg, MD, USA 
Hyclone	   Logan, UT, USA 
Invitrogen	   Carlsbad, CA, USA 
PerkinElmer	   Waltham, MA, USA 
Pierce	   Rockford, IL, USA 
Santa Cruz Biotechnology	   Santa Cruz, CA, USA 
Sigma-Aldrich	   St. Louis, MO, USA 
The Jackson Laboratory	   Bar Harbor, ME, USA 
VWR	   West Chester, PA, USA 
 
Table 2.2 Company name and address. 
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Primary Antibody	   Dilution	   Supplier	  
MAO-A (H-70)	   1:1000 Santa Cruz Biotech 
C-Myc	   1:500 Santa Cruz Biotech 
FLAG	   1:500 Sigma-Aldrich 
β-­Actin	   1:3000 Sigma-Aldrich 
PS-1-loop	   1:1000 (CHEMICON 
International) 
Secondary Antibody	   Dilution Supplier 
Donkey Anti-Goat IgG	   1:2000 Santa Cruz Biotech 
Goat Anti-Rabbit IgG	   1:2000 Cedarlane Laboratories 
Goat Anti-Mouse IgG	   1:2000 Cedarlane Laboratories 
 
Table 2.3 List of antibodies, dilutions and suppliers. 
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MAO-A/B cDNA were amplified in the pCMV/myc/mito and pcDNA3.1 (+) 
mammalian expression vectors.  Based on multiple sequence alignment and identification 
of a potential motif that mediates the interaction between PS-1 and MAO-A, wildtype 
MAO-A cDNA was then used to generate the substitutions within this motif, e.g. A302S. 
The complementary sequence in MAO-B cDNA was used to generate the S293A mutant 
(so that it resembled the motif in MAO-A). 
 
2.1.3 Animals. 
Knock-in mice (M146V) overexpressing human PS-1 mutant were purchased 
from the Jackson Laboratory. The transgene contains a mouse Thy1 promoter that drives 
the expression of human PS-1 with the amino acid substitution of Valine (V) for 
Methionine (M) at position 146 (M146V). The homozygous and wildtype lines were 
obtained from crossing heterozygous mice. Genotypes were routinely confirmed by PCR 
and restriction analysis (Figure.2.1). Because of the dominant effect of the transgene, 
hetero- and homozygous mice were pooled for the purposes of these studies. 
Animals were housed in a 12h light/dark cycle at 20°C. Food and water were 
available ad libitum. Each procedure was followed within the guidelines established by 
the Canadian Council on Animal Care and approved by the University of Saskatchewan 
Committee on Animal Care and Supply. 
 
2.2 Methods. 
2.2.1 Cell culture. 
  Cells were cultured in 10 cm Falcon tissue culture plates and incubated at 37°C, 
under 5% CO2 atmosphere. Except for the PC12 cell line, all cell lines were cultured in 
low glucose Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine 
serum.  The medium for PC12 cells is supplemented with 15% horse serum and 2.5% 
fetal bovine serum (FBS) in Ham’s F-12 (Kaighn’s Modification) medium.  The culture 
plates for PC12 cells were pre-coated with rat-tail collagen to enhance cell adhesion.  
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For adherent cultures including HT-22 and HEK, medium was removed and 
discarded and the cells were rinsed with a balanced salt solution (PBS). Cells were 
washed by gently rocking the plate  and then discarding  the washing solution. Cells were  
 
 
 
 
 
 
 
 
 
Figure 2.1: Genotyping of the PS-1(M146V) mice. Genomic DNA was extracted from 
tail snips. The PS-1 gene was first amplified by PCR and then digested with the 
restriction enzyme Eco 91I (note that the mutation in the codon that leads to the M-to-V 
substitution introduces an Eco 91I restriction site). Lane 1 and 2 are wildtype mice (no 
mutation, so no restriction by Eco 91I). Lane 3 has an unrestricted band (wildtype) and 
two smaller bands (a restricted allele), which indicates it is a heterozygous mouse. Note 
that as the two lower bands (in Lane 3) are restricted fragments of the upper band, that 
their combined ‘weight’ is equal to that of the upper band.  Lane 4 has no wildtype band, 
but has the two lower ‘restricted’ bands, which indicates it is a homozygous mouse. 
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detached by incubating with Trypsin-EDTA at 37°C for 2-3 min. Equal volumes of 
culture medium were added to terminate the digestion. The detached cells were 
resuspended in complete growth medium by pipetting repeatedly over the surface. The 
cells were then passaged to new plates and returned to 37ºC in the 5% CO2 atmosphere 
humidified incubator. Cell stock, when needed, was made using Cell Freezing Media, and 
the cells were then stored in liquid nitrogen. 
 
2.2.2 Site-directed mutagenesis.   
All of the mutants were generated using the Quikchange® Site-Directed 
Mutagenesis Kit. The MAO-A A302S (Alanine to Serine) mutant was generated from the 
wildtype MAO-A cDNA that had been subcloned into the pCMV/myc/mito mammalian 
expression vector. MAO-B S293A (Serine to Alanine) was generated from the 
corresponding wildtype MAO-B-myc cDNA.  
    All pairs of primers for use in the amino acid substitution are designed individually 
according to the PCR based site-directed mutagenesis protocol (i.e. length and GC 
content).  
The primers were as follows (mutated codons are underlined and highlighted in 
red): 
For the MAO-A A302S substitution: 
Forward: 5′-TT CCA ATG GGA TCT GTC ATT AAG TGC ATG-3′ 
Reverse:  3′-CAT GCA CTT AAT GAC AGA TCC CAT TGG AAG-5′ 
For the MAO-B S293A substitution: 
Forward: 5′-ACT CGT GTG CCT TTG GGT GCA GTC ATC AAG TGT ATA G-3′ 
Reverse:  3′-TAT ACA CTT GAT GAC TGC ACC CAA AGG CAC ACG AG-5′ 
 
The complimentary oligonucleotides were used to generate the desired mutation 
by PCR. Each sample tube contains 5 µL of 10X reaction buffer, 2 µL of plasmid dsDNA 
template (50 ng), 1 µL of forward primer (125 ng), 1 µL of reverse primer (125 ng), 1 µL 
of dNTP mix solution and 39.5 µL double-distilled water to a final volume of 50 µL. 
Following vortexing, the tube was centrifuged briefly and 1 µL of Pfu Turbo DNA 
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polymerase (2.5 U/µL) was added. Thermal cycling was as follows. At the end of the 
reaction, the tube was immediately placed on ice for 2 min to cool the sample. 
 
First step: 1 cycle   95ºC for 30 seconds 
Second step: 16 cycles  95ºC for 30 seconds 
55ºC for 1 minute 
68ºC for 7 minutes 
 
Following temperature cycling, the cDNA product was treated with 1 µL of the 
Dpn I restriction (10 U/µL) for 1h at 37°C to digest the methylated parental DNA 
template and to select for the PCR-generated (non-methylated) DNA. After digestion, 1 
µL of the Dpn I-treated DNA was added to 50 µL of the super-competent E. coli bacteria 
(provided with the transformation kit) and incubated on ice for 30 min. After the 
incubation, the reaction was heat-shocked for 45 sec at 42°C and kept on ice for another 2 
min. The bacteria were grown in 250 µL of SOC medium (980 µL SOB (950 mL ddH2O; 
20 g Bacto Tryptone; 5 g Bacto Yeast Extract; 0.5 g NaCl; 10 µL 2 M MgCl2; 20 µL 1 M 
glucose) at 37°C, and agitated at 225 rpm for 45 min. The bacteria were then incubated 
on Luria-Bertani Broth (LB)/Amp+ agar plates overnight. Positive colonies (those 
colonies that grew are ampicillin resistant and, thus, contain the plasmid DNA) were 
selected on the following day.  
 
2.2.3 Mini-prep amplification of plasmid DNA. 
Mini-preparation (Mini-prep) was used to isolate small amounts of plasmid DNA 
from bacteria while limiting contamination by protein and genomic DNA. A single 
positive colony was picked and cultured in 3 mL of LB (10 g Bacto Tryptone; 5 g Bacto 
Yeast Extract; 10 g NaCl; taken to 1000 mL H2O) (containing 50 µg/mL ampicillin). 
After shaking at 37°C/250 rpm overnight, 1 mL of culture was centrifuged at 12,000g for 
30 sec. The cell pellet was fully resuspended in 100 µL of ice-cold solution I (50 mM 
Glucose; 10 mM EDTA, pH 8.0; 25 mM Tris-base, pH 8.0) by vortexing. The cells were 
then lyzed by gently mixing the tube back and forth 10 times with solution II (0.2 N 
NaOH; 1% sodium dodecyl sulfate (SDS)). Following a 5-min incubation on ice, 150 µl 
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of ice-cold solution III (5 M potassium acetate solution, pH 4.8) was added to the tube 
and mixed by rapidly inverting the tube 10 times. The sample was centrifuged at 12,000g 
for 5 min at 4°C and the supernatant was transferred to a new microtube. 450 µL of 
phenol:chloroform (1:1) was added to the tube to purify the plasmid DNA. After 
centrifugation at 12,000g for 2 min, the supernatant was transferred to a new tube and 
900 µl of room temperature 100% ethanol was used to precipitate the double-strand 
DNA. The DNA pellet was collected by centrifuging at 12,000g for 10 min and washing 
with 1mL of ice-cold 85% ethanol. The purified DNA was then re-dissolved in nanopure 
water containing DNAse-free pancreatic RNAse (20 U/mL) and incubated for 20 min at 
room temperature. The plasmid yield was measured by UV-spectrometry at an 
absorbance of 260 nm.  An O.D. ratio of 260 nm: 280 nm was also determined to 
measure the DNA purity (a ratio of 1.8 or greater was deemed to have minimal protein 
contamination and could be used for transfection experiments). 
 
 2.2.4 Maxi-prep amplification of plasmid DNA. 
The procedure for plasmid DNA maxi-prep is similar to that described above for 
the mini-prep. Cells were cultured in 5 mL antibiotic-LB broth for 5 h and then 
transferred into 300-400 mL LB medium to grow for 18 h. Cells were harvested by 
centrifugation [5000g for 10 min at 4ºC] and washes in 100 ml ice-cold 1X STE (0.1 M 
NaCl; 10 mM, Tris pH 8.0; 1 mM EDTA, pH 8.0). The pellet was lysed with solution I 
(20 mL), solution II (40 mL) and solution III (20 mL) sequentially (solutions as described 
for the mini-prep protocol, above), then was centrifuged for 15 min at 5000g at room 
temperature. The supernatant was filtered through six layers of cheesecloth into a 250 mL 
centrifuge bottle. 0.6-volume of isopropanol was added and incubated for at least 15 min 
to precipitate liberated DNA and RNA. Following centrifugation at 5000g for 15 min, the 
pellet was collected and rinsed with 85% of ethanol. The ethanol was drained and the 
pellet was re-dissolved in 3 mL of TE buffer (10 mM Tris-base, pH 8.0; 1 mM EDTA, 
pH8.0). The RNA was precipitated in 4.8 mL ice-cold 5 M LiCl and centrifuge at 9000g 
for 10 min at 4ºC. The plasmid DNA in the supernatant was subsequently precipitated 
with an equal volume (about 7.8 mL) of isopropanol again and was washed with 85% 
ethanol. After fully draining the ethanol, 500 µL of TE buffer was added to re-suspend 
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the DNA pellet. The sample was treated with 5 µL RNase (10 mg/mL) for 30 min at 
room temperature. Immediately after, 400 µL of 1.6 M NaCl (with 13% (w/v) PEG 800) 
was mixed with the TE solution and centrifuged at 12,000 rpm for 2 min. Plasmid DNA 
was purified by two extractions into 500 µL phenol. Chloroform was used to separate 
phenol from the DNA solution. The concentration of DNA was measured by UV-
spectrometry at an absorbance of 260 nm. 
 
2.2.5 Transformation of bacterial cells. 
Transformation is a technique routinely used to amplify a gene of interest in 
molecular biology. The plasmid that contains a specific DNA sequence was inserted into 
bacterial competent cells (thus ‘transforming’ the bacteria) through artificially induced 
membrane pores as follows. 1µL of plasmid DNA was combined with 50 µL competent 
DH-5α E. coli cells in each transformation reaction. After 30 min of incubation on ice, 
the reaction tube was then heat-shocked at 42°C for 45-60 sec. In order to allow the cell 
membrane to heal, a 2-min incubation on ice was needed. Then cells were cultured in 250 
µL of SOC medium at 37°C for 45 min with shaking at 225 rpm. 30 µL of the cell 
suspension was spread on an agar plate (containing the appropriate antibiotic) and grown 
in an incubator (37°C) overnight. Individual colonies were collected and subjected to 
PCR to confirm the presence of the plasmid. 
 
2.2.6 Transient transfection of mammalian cultures. 
For this part of the project, plasmid DNA was transferred into mammalian cells, 
e.g. N2a and HT-22 cells. The protein wa s then allowed to be expressed for 24 hours 
(hence, ‘transient’ transfection). 3x106 cells were plated in 100 mm cell culture dishes. 
DNA and Lipofectamine 2000 reagent were diluted to a predetermined concentration in 
separate microcentrifuge tubes (for a final ratio of DNA:Lipofectamine 2000 of 1.5 
µg:2.5 µL) with serum-free OPTI-MEM medium and incubated for 5 min. The two 
solutions were then combined at room temperature for 20 min to allow for the formation 
of DNA-Lipofectamine 2000 complex. The mixture was added directly into each cell 
culture and the culture medium was replaced 4 hours after the transfection to avoid any 
toxicity associated with the Lipofectamine 2000 reagent. 
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2.2.7 Immunoblot/Western Blot assay. 
Immunoblot/Western Blot is a powerful technique for examining a protein of 
interest. Equal amounts of denatured protein from total cell lysates were resolved on an 
SDS-polyacrylamide gel (SDS-PAGE: the proteins migrate based on their molecular 
weight). The resolved proteins were probed using specific antibodies the target the 
protein and secondary antibodies (i.e. antibodies that recognize the specific primary 
antibody and that have been conjugated with horseradish peroxidase to allow for a 
chemiluminescent reaction) were used to reveal the protein band on photographic film. 
Briefly, transfected cells were harvested and washed with 1X PBS. Following 
centrifugation at 1000g for 5 min at room temperature, the supernatant was removed and 
the cell pellet was lyzed with Lysis buffer (1% Triton-X 100; 20 mM Tris, pH 7.5; 10% 
glycerol; 1 mM EDTA) containing 100X protease inhibitor cocktail. The lysate was 
vortexed and incubated on ice for 30 min; then centrifuged at 16,000g at 4 ºC for 20 min. 
The supernatant was retained as it contained the soluble protein. The protein 
concentration was determined by BCA protein assay kit. Each sample was denatured by 
heating to 95ºC for 5 min with 4X Laemmli Buffer (8% SDS; 40% glycerol; 10% 
mercaptoethanol; 0.02% bromophenol blue; 0.25 M tris-HCL, pH 6.8).  
The Mini-PROTEAN Tetra electrophoresis system and Mini Trans-Blot Cell 
system were both used (with comparable results) for the electrophoresis and transfer. A 
10% resolving gel (4mL ddH2O; 2.50 mL Buffer A (18.45 g Tris-HCL; 77 g Tris-base; 2 
g SDS; 500 mL H2O; pH 8.8); 3.33 mL 30% acrylamide; 100 µL 10% SDS; 50 µL 10% 
APS; 10 µL TEMED) and 4% stacking gel (3 mL ddH2O; 1.25 mL Buffer C (30g Tris-
base 2 g SDS; 500 mL H2O, pH 6.8); 0.67 mL 30% acrylamide; 50 µL 10% SDS; 25 µL 
10% APS; 5 µL TEMED) were prepared. Running buffer was made by mixing 3.03 g 
Tris-base, 14.4 g glycine and 10 g SDS in a final volume of 1000 mL H2O. The proteins 
were resolved by SDS-PAGE electrophoresis (at a constant voltage of 110V for 1.5 to 2 
h). Proteins were then transferred onto a 0.22 µm nitrocellulose membrane at a constant 
current of 230 mA for 1.5 h in ice-cold running buffer (3.03 g Tris-base; 14.4 g glycine; 
10 g SDS; taken to 1000 mL with H2O).  
Membranes were blocked with 5% (m/v) skimmed milk in TBS buffer (3 g Tris-
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base; 8 g NaCl; taken to 1000 mL with H2O) for 1h at room temperature and then 
incubated with a 1:1000 dilution of the antibody in TBS-Tween® 20-0.5% bovine serum 
albumin (BSA) overnight at 4ºC. The membranes were washed three times for 10 min 
with TBST and then incubated with a 1:2000 dilution of the secondary antibody in 5% 
milk-TBST for another hour at room temperature. Following three washes with TBST, 
the membranes were processed by enhanced chemiluminescence (ECL) and exposed to a 
film. All of the washing and incubation steps were carried out on a shaker.  
 
2.2.8 Immunoprecipitation. 
Immunoprecipitation (IP) is a technique used to investigate whether two proteins 
physically associate, and/or to confirm the biochemical characteristics, posttranslational 
modifications and expression levels of a given protein. IP involves the targeting of a 
protein by a specific antibody and then precipitation of the immune complex with 
sepharose beads on which have been attached either protein-G or protein-A (bacterial 
derived proteins that bind the Fc portion of mammalian IgG antibodies). 
Cells were harvested and lysed as usual (see 2.2.7). For each IP sample, 300-500 
µg of protein was prepared. Non-specific mouse IgG at a ratio of 1:100 (antibody: 
protein) and 30-50 µL of sepharose-A/G were added to the lysate for pre-clearing of the 
protein extract at 4ºC for 1-2 h (preclearing removes any non-specific reaction between 
antibody, speharose and protein). 5-10 µg of antibody was incubated overnight (4ºC) with 
the pre-cleared extract, following which 50 µL of washed protein-A/G beads were added 
to the sample. The samples were then incubated (with shaking for 1 h at 4ºC) and then the 
beads were pelleted by centrifugation at 9000g for 5 min and then resuspended in lysis 
buffer. This was repeated three times. After the last wash, the beads were boiled at 95ºC 
for 5 min with 25 µL of 1X loading buffer. 
 
2.2.9 MTT conversion assay.  
MTT conversion was used as an indicator of mitochondrial function/cell viability. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) stock (5 mg/mL) 
was prepared by dissolving MTT in PBS and filtering this solution through a 0.22 µm 
filter to remove the minute traces of undissolved MTT. The working solution (0.5 
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mg/mL) was made by mixing 1 volume of stock MTT solution with 9 volumes of DMEM 
media containing 1% FBS. 
Cells were first seeded in a 96-well plate and grown overnight in 5% CO2 
incubator. After treatment of cells for 24 h, experimental media was carefully removed 
and 50 µL of the MTT working solution was added to each well. The cells were then 
incubated in a 5% CO2 incubator at 37ºC for 4 h. 100 µl of DMSO was added and 
thoroughly mixed to dissolve the purple formazan crystals generated by conversion of the 
MTT substrate.  The plates were immediately read at an absorbance of 570 nm. These 
values were used to estimate cell viability. The average OD values of control group 
(vector transfected cells) were set to 100% of cell viability.  
 
2.2.10 MAO-A activity assay. 
MAO-A catalytic activity was assessed using a radioenzymatic protocol. The 
enzymatic rate of conversion of MAO-A to aldehydes is estimated using [14C]-labeled 
serotonin (5-HT) as the substrate and a potassium phosphate reaction buffer (181.6 ml 
1M K2HPO4, 18.4 ml 1M KH2PO4, taken to 1000 ml with H2O, pH 7.85). The buffer 
must be oxygenated for 30 min at room temperature before use [127]. 100 µg protein 
homogenates (in 50 µl oxygen-saturated potassium buffer) were incubated with 50 µl 
serotonin (0.25 mM 5-HT and 25 nCi of [14C]-5-HT) at 37 °C for 10 min. The reaction 
was terminated by acidification (10 µl of 3M HCL). The radiolabeled aldehyde 
metabolite was extracted into 1 ml of H2O-saturated ethyl acetate:toluene (1:1) solution. 
The sample was mixed by vortexing and centrifuging at 14,000g for 30 seconds. After 
centrifugation, 700 µl of top layer (organic phase) was transferred to a liquid scintillation 
vial containing 4 ml of scintillation cocktail. The amount of radioactive metabolite, 
estimated as dpm (disintegrations per minute), was measured on a Beckman counter. The 
blank control was made by mixing protein with substrate, but the reaction was quenched 
by acidification before it could take place. The standard was 50 µl of radiolabeled 
serotonin substrate. The activity of MAO-A was calculated based on the formula: 
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Ca2+-sensitive MAO-A activity was determined by pre-incubation of the homogenates 
with 1 mM Ca2+ for 20 min at room temperature prior to the reaction [128, 129]. 
 
2.2.11 Brain regional dissection.  
Brains were rapidly removed from the test mice and were placed on a cutting 
platform, which was kept cold on dry ice. After removing the cerebellum from the 
brainstem, the blade was carefully inserted into the central sulcus and used to separate the 
brain in two (saggitally). Although various regions were collected (hippocampus, 
striatum), only the cortex and cerebellum were used for the current project. All samples 
were flash-frozen and stored at -70°C until assayed. 
 
2.2.12 High-pressure liquid chromatography (HPLC). 
 HPLC determinations were performed using a Bioanalytical Systems (West 
Lafayette, IN, USA) LC-4B amperometric detector and a Hewlett-Packard (Palo Alto, 
CA, U.S.A.) 3392A integrator. The compounds of interest were measured using a glassy 
carbon electrode set at 0.75 V versus an Ag/AgC1 reference electrode. The flow rate was 
l ml/min through a C18 column (4.6 mm x 250 mm; 5 µm particle size, Applied Science 
Labs, Avondale, PA, USA) coupled to a precolumn. The mobile phase consisted of 
NaH2PO4 (55 mM), sodium octyl sulfate (0.85 mM), disodium EDTA (0.37 mM) and 
acetonitrile (9%) and was filtered, degassed, and adjusted to pH 3.0. The concentrations 
of analytes were determined by comparing peak height ratios to those of a set of authentic 
standards processed in parallel [130]. These analyses were done in collaboration with Dr. 
G.B. Baker (Neurochemical Research Unit, Psychiatry, University of Alberta). 
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2.2.13 Immunohistochemistry. 
Sagittally separated brains were fixed and sliced with the help of Tuo Zhao 
(another M.Sc. student in our laboratory). Animals were first perfused with 0.1 M PBS 
(pH 7.4) and then brains were post-fixed in paraformaldehyde (4%: 24 h). The brains 
were then transferred to cryoprotectant (30% glycerol/0.1M phosphate buffer, 48 h), then 
snap-frozen and stored at -70ºC until sectioned (30 µm, coronally). The sections were 
then stored (25% glycerol; 25% ethylene glycol; 0.1M PBS) at 4ºC until processed. 
3,3′-Diaminobenzidine (DAB)-immunohistochemistry was performed on free-
floating sections that had been rinsed in 0.01 PBS, treated with 0.2% H2O2 in 0.1M PBS 
(30 min) and blocked in 5% normal serum in PBS containing 0.2% Triton (PBS-TX) (1.5 
h). Sections were then incubated (4ºC) for 72 h with the polyclonal H-70 MAO-A 
antibody (1:100) in 5% normal serum-PBS-TX, and then incubated with biotinylated goat 
anti-rabbit (BA-1000, Vector Laboratories Canada) (1:250, 1.5 hours) and processed by 
the ABC-DAB method. All steps were followed by washes in PBS (3x20 min). The 
sections were also processed for thionin/Nissl staining. Sections were mounted on 
gelatin-coated slides, dehydrated in ascending alcohols, cleared with xylene, and 
coverslipped with Permount for visualization using a Olympus BX51 fluorescence 
microscope. 
 
2.1.14 Forced-swim test.  
The forced swim test, originally developed by Porsolt and colleagues to screen for 
antidepressant drugs [131], is a behavioural test designed to measure ‘despair’. After the 
drug treatment, animals are placed in a tank of water that does not allow them to touch 
the bottom. They are tested for an extended period of time and observed for their 
mobility, i.e. making ‘swimming’ movements to keep their head above the water. The 
time that the rodents spend ‘swimming’ is recorded. The time that animals are immobile 
can be decreased by antidepressants and, hence, was thought to be a good assay for 
antidepressant drugs [131]. For my studies, a glass cylinder (46 cm tall x 20 cm in 
diameter) was used. The cylinder contained 30-cm deep water and was maintained at 
22°C. Clorgyline (CLG: 1 mg/kg, i.p.) was administered acutely (2 h before the testing 
priod) to 6-month old wildtype and PS-1(M146V) mice. This dose-regimen of CLG was 
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chosen as it does not affect either immobility time in the Forced-Swim Test [132] or 
ambulatory behaviour [133] in wildtype mice, but it does affect the tissue content of 
monoaminergic neurotransmitters [133]. Mice were timed concurrently by four 
independent observers. The water was changed between test runs. 
 
2.1.15 Statistical analyses. 
Data were analyzed by unpaired t-test (for comparing between two means) or one-
way analysis of variance (AVOVA) (for comparing between more than two means). t-test 
statistics are reported as, for example, [t=3.168, df=8, P=0.0132], where ‘t’ is the test 
value, ‘df’ are the degrees of freedom, and ‘P’ is the corresponding probability. F-test 
statistics are reported as, for example, [F(3,19)=0.7126, P=0.5586], where ‘F’ is the test 
value, ‘(3,19)’ are the degrees of freedom between groups (number of groups minus ‘1’, 
so 4 groups -1 = 3) and within samples (total number of samples minus ‘1’, so 20 
samples -1 = 19), and ‘P’ is the corresponding probability. A P value (probability, i.e., a 
number expressing the chances that a specific event will occur) of less than 0.05 was set 
as statistically significant (e.g. there is less than a 5% (0.05) chance that an effect is due 
strictly to random chance). Post-hoc analysis relied on the Bonferroni’s Multiple 
Comparison Test (PRISM v3.0; GraphPad Software Inc., San Diego, CA, USA). The 
Bonferroni’s Multiple Comparison Test was used as it is a very stringent statistical test 
and any conclusions based on this test are certainly reliable. All data were expressed as 
means ± SEM (unless otherwise indicated). Symbols were used according to convention, 
i.e.*: P<0.05, **: P<0.01, ***: P<0.001. 
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3. Results 
Part I: Effects of PS-1 (M146V) variant on MAO-A function in mice. 
3.1 MAO-A activity is affected in the PS-1 (M146V) knock-in mice. 
A previous M.Sc. student in our research group, Geraldine Gabriel, originally 
tested the effects of four PS-1 mutants (D257A, Y115H, ∆Ex9 and M146V) on MAO-A 
function. She found that the endogenous MAO-A activity in HT-22 cells was altered 
differently by these PS-1 constructs [134]. The PS-1(M146V) protein did not alter HT-22 
MAO-A activity compared to the vector-transfected control, but did have an effect on 
increase calcium (Ca2+)-sensitive MAO-A activity. There is evidence that a significant 
disruption of Ca2+ homeostasis can be observed in PS-1 (M146V) mice [105]. Since PS-1 
(M146V) is clearly associated with familial AD and the animal model also is available 
commercially, I chose to start my studies by examining Ca2+-sensitivity of MAO-A in the 
PS-1(M146V) mouse at two different ages. In order to ensure that any changes would be 
independent of any change in Aβ burden and, thus, only due to the expression of the 
mutant PS-1 protein, 3- and 6-month old were chosen for the following experiments. 
Cortical and cerebellar tissues from 3-month and 6-month-old wildtype and PS-
1(M146V) mice were tested for both basal and Ca2+-sensitive MAO-A activity. In 
cortical homogenates, activity did not change in either wildtype or 3-month PS-
1(M146V) mice. However, Ca2+-sensitive MAO-A activity was increased in 6-month PS-
1(M146V) mice by approximately 25% (Figure 3.1) [F(3,19)=6.286, P=0.0051]. In 
cerebellar homogenates, neither basal or Ca2+-sensitive MAO-A activity was affected 
(Figure 3.1) [F(3,19)=0.7126, P=0.5586]. Therefore, 6-month old mice were used for the 
remainder of the experiments.  
MAO-A protein level was also analyzed by immuno- (Western) blot (Figure 3.2). 
The protein amount from cortical extracts in PS-1(M146V) 6-month old mice was 
increased approximately 50%, as assessed by ImageJ 1.32j densitometry 
(http://rsb.info.nih.gov/ij/) [t=3.168, df=8, P=0.0132]. Therefore, two conclusions can be 
immediately made: first, the PS-1(M146V) protein appears to affect MAO-A activity in 
vivo, and, second, the mismatch between MAO-A protein induction (~50%) and MAO-A 
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catalytic activity (no change in basal activity) suggests a potential post-translational 
regulation of MAO-A function.  
 
3.2 Nissl/thionin staining in wildtype and PS-1 (M146V) mouse sensorimotor 
cortex. 
Since MAO-A activity was found to be different in the cortex between wildtype 
and PS-1(M146V) mice, tissue sections were taken from 6-month old mice cortex for 
determining protein expression by immunohistochemistry. Nissl staining is used to reveal 
"Nissl bodies" (rough endoplasmic reticulum) which are abundant in neurons; this 
technique is often used to examine and reveal specific patterns of cytoarchitecture in the 
brain. Examination (40X and 100X) of wildtype cortex reveals a distinct architecture of 6 
layers (Figure 3.3B,C). In contrast, cells from the same region in the PS-1(M146V) 
mouse cortex appear to be disorganized and the laminar boundaries are lost (Figure 
3.3E,F). These cortical sections were also used for DAB-MAO-A immunohistochemistry 
(Figure 3.3A,D). While MAO-A immunodetection was apparently concentrated in layer 
V of wildtype cortex, an abnormal distribution of the MAO-A protein was observed in 
PS-1(M146V) cortex. It is clear that the presence of the PS-1(M146V) transgene affects 
cortical structure and that this also has an effect on MAO-A distribution (and perhaps 
function). MAO-A function in these animals was tested in the next section. 
 
3.3 The MAO-A inhibitor clorgyline (CLG) exerts behavioural changes in PS-
1(M146V) mice. 
The forced-swim test was used to examine non-cognitive behaviours in the PS-
1(M146V) mice. It is a test of behavioural despair (akin to depression in humans). 
Treatments [saline or CLG (1 mg/kg), n=6-9] were administered 2 hr prior to a 6-min test 
swim (includes a pre-exposure period of 2 minutes followed by a 4-minute test session 
immediately thereafter). Saline solution was given to the control animal group as vehicle 
treatment. Mice were placed in the water and the time that they spent ‘swimming’ was 
recorded. Figure 3.4 suggests that wildtype mice (black bars) perform the same regardless 
of treatment. In contrast, CLG decreased the time that PS-1(M146V) mice (grey bars) 
spent swimming [F(3,24)=3.425, P=0.0359]. 
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Figure 3.1: MAO-A activity with and without Ca2+ in wildtype and PS-1 (M146V) 
mice. Cortical extracts from 3- and 6-month old mice expressing the PS-1(M146V) 
protein were assayed for MAO-A activity. The Ca2+-sensitive activity was only increased 
in cortex of 6-month old PS-1(M146V) mice (M/V, 6). The effect of PS-1(M146V) 
appears to be age-dependent as well as region-dependent as there was no obvious effect 
of the transgene on MAO-A activity in cerebellar extracts. *: P<0.05 versus Ca2+-
sensitive MAO-A activity in WT cortical extracts (mean±SEM, n=5-6). 
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Figure 3.2: MAO-A expression in cortex and cerebellum of PS-1(M146V) mice. 
Endogenous MAO-A protein in cortex (A) and cerebellum (B) region in 6-month old 
wildtype (WT) and PS-1(M146V) (M/V) mice was detected using Western blot analysis 
based on the MAO-A H-70 antibody. (C) Densitometry reveals that cortical MAO-A 
expression increases by approximately 50% in PS-1(M146V) mice. *: P<0.05 versus 
wildtype levels (n=5). 
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Figure 3.3: MAO-A distribution and Nissl staining in wildtype and PS-1(M146V) 
mice sensorimotor cortex. Coronal cortical sections of (A-C) wildtype and (D-F) PS-
1(M146V) mice were used for Nissl staining (B, C, E, F) and DAB-MAO-A 
immunohistochemistry (A, D). Scale bars=125 µm (A, B, D, E; 100X magnification) and 
500 µm (C, F: 40X magnification). 
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Figure 3.4: MAO-A-sensitive non-cognitive behaviour is revealed in the PS-
1(M146V) mice. 6-month-old PS-1(M146V) (M/V) mice and wildtype (WT) littermates 
were treated with either the saline vehicle (VEH) or the selective MAO-A inhibitor 
clorgyline (CLG; 1 mg/kg, i.p., 2 h). Their ‘activity’, i.e. the time that they spent 
swimming during the 240 sec test period of the forced-swim test (FST), was measured. 
Western blot/Immunoblot (IB) demonstrates MAO-A protein expression in 
corresponding cortical extracts. β-Actin is used to demonstrate equal protein loading 
across lanes. *: P<0.05 versus vehicle-treated PS-1(M146V) mice (mean±SEM, n=6-8). 
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3.4 Levels of selected monoamine and acid metabolites in the cortex and 
cerebellum of wildtype and PS-1(M146V) mice. 
Figure 3.1 suggests that expression of the PS-1(M146V) protein affects MAO-A function 
in a region-specific manner. As MAO-A is known to degrade monoamine such as 5-HT, 
dopamine (DA) and norepinephrine (NE), it was important to determine the whether 
these monoamines were affected in the PS-1(M146V) mouse. The cortex and cerebellum 
from the 6-month wildtype and PS-1(M146V) mice that had been subjected to the forced-
swim test were immediately sacrificed and used for neurochemical analyses using high-
pressure liquid chromatography. In addition to the monoamines listed above, acid 
metabolites of 5-HT, i.e. 5-HIAA (5-hydroxyindolacetic acid), and DA, i.e. DOPAC (3,4-
dihydroxyphenylacetic acid) and HVA (homovanillic acid), were also measured. This 
work was done in collaboration with Dr. G.B. Baker (Neurochemical Research Unit, 
Psychiatry, University of Alberta. 
The statistics for 5-HT and 5-HIAA levels in cortical extracts were as follows: 5-
HT [F(3,36)=12.99, P<0.0001] and 5-HIAA [F(3,39)=18.95, P<0.0001] (Figure 3.5). For 
5-HT and 5-HIAA levels in cerebellar extracts, the statistics were as follows: 5-HT 
[F(3,36)=9.331, P=0.0001]; 5-HIAA [F(3,36)=2.390, P=0.0864] (Figure 3.5). The statistics 
for DA, NA and metabolite levels in cortical extracts were as follows: DA 
[F(3,30)=2.266, P=0.1035], DOPAC [F(3,33)=5.540, P=0.0041], HVA [F(3,37)=6.528, 
P=0.0013], NA [F(3,38)=5.017, P=0.0054] (Figure 3.6). For DA, NA and metabolite 
levels in cerebellar extracts, the statistics were as follows: DA [F(3,34)=8.963, 
P=0.0002], DOPAC [F(3,32)=0.664, P=0.5929], HVA [F(3,34)=2.810, P=0.0557], NA 
[F(3,30)=34.63, P<0.0001] (Figure 3.6). Post hoc analyses revealed that the PS-1(M146V) 
knock-in exerted changes in cortical amine and metabolite levels that, in general, 
resemble characteristic MAO inhibition, i.e. amine levels increase while corresponding 
metabolite (DOPAC and 5-HIAA) levels decrease (Figs. 3.5 & 3.6). Similarly, treatment 
with CLG resulted in characteristic changes in catecholamine levels, but, surprisingly, did 
not significantly affect the levels of 5-HT or 5-HIAA. This pattern of change was 
inconsistent with the changes observed in cerebellar extracts, wherein the PS-1(M146V) 
variant tended to generally decrease the levels of these amines and metabolites, whereas 
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treatment with CLG only resulted in the accumulation of 5-HT and NA. These data 
suggest that PS-1(M146V) functionally inhibits cortical MAO-A and that acute treatment 
with CLG elicits region-specific (and potentially uncharacteristic) effects on 
monoaminergic metabolism in this model. 
 
3.5 Clorgyline (CLG) is more potent in PS-1 (M146V) mice than in wildtype 
mice. 
Cortical and cerebellar homogenates from 6-month wildtype and PS-1(M146V) 
mice were tested ex vivo for MAO-A activity to confirm that they had received the 
treatments according to Figures 3.4, 3.5 & 3.6.  
With wildtype cortical homogenates it was observed that the MAO-A activity 
decreased by approximately 50% (compared to the vehicle-treated group) after treatment 
with CLG [F(3,18)=20.02, P<0.0001]. Unexpectedly, MAO-A activity was almost 
completely inhibited in the CLG-treated PS-1(M146V) mice (Figure 3.7A). In 
cerebellum, the CLG had a very similar effect as determined for the cortex (Figure 3.7B) 
[F(3,16)=36.87, P<0.0001]. Thus, the potency of the MAO-A-selective inhibitor CLG is 
increased by the PS-1(M146V) protein in vivo. 
 
3.6 CLG dose-response curves in wildtype and PS-1(M146V) mice. 
CLG dose-response curves (n=4) were generated using the cortical extracts from 
vehicle-treated wildtype and PS-1(M146V) mice in Section 3.5 above. The cortical 
extracts were pre-incubated with CLG (final concentration ranging from 10-8 to 102 µM) 
for 20 min at room temperature. CLG dose-response curves using cortical extracts from 
WT [R2=0.9987] mice and PS-1(M146V) [R2=0.9988] mice revealed logIC50 values 
(µM) of -2.39 (±0.073) and -1.95 (±0.045), respectively, which, although statistically 
significant [t=11.44, df=6, P<0.0001], is not a pharmacologically substantial shift in the 
response curve (Fig. 3.8). The respective Hill coefficients were -0.827 (±0.084) and -
1.209 (±0.187) [t=3.734, df=6, P=0.0097]. This difference suggests a change in 
cooperativity. 
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Figure 3.5: Cortical and cerebellar levels of indoleamines. Serotonin (5-HT) levels 
and its MAO-A-mediated acid metabolite 5-HIAA were measured by HPLC in cortical 
(left) and cerebellar (right) extracts from both wildtype (WT) and PS-1(M146V) (M/V) 
mice treated with either the saline vehicle (black bars) or the MAO-A inhibitor clorgyline 
(grey bars: 1 mg/kg, 2 h, grey bars). **: P<0.01, ***: P<0.001, between indicated groups 
(mean±SEM, n=8-13). 
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Figure 3.6: Cortical and cerebellar levels of catecholamines. Levels of DA and its two 
acid metabolites (DOPAC & HVA) as well as levels of NA were examined in cortical 
and cerebellar tissue of 6-month old wildtype and PS-1(M146V) mice. Both of the groups 
of mice were injected with saline vehicle (black bars) or 1 mg/kg of clorgyline (grey 
bars) for two hours at which point they were sacrificed for neurochemical analyses. *: 
P<0.05; **: P<0.01, ***: P<0.001, between indicated groups (mean±SEM, n=8-13). 
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Figure 3.7: The potency of CLG is increased by the PS-1(M146V) protein in vivo. 
The extent of inhibition of MAO-A activity was tested in (A) cortical and (B) cerebellar 
tissue extracts from wildtype (WT) or PS-1(M146V) mice used for behavioural and 
neurochemical analyses in previous experiments. CLG is more potent in both the cortex 
and cerebellum of PS-1(M146V) mice. *: P<0.05; **: P<0.01, ***: P<0.001, versus the 
respective vehicle (VEH)-treated group or between indicated groups (mean±SEM, n=8-
13). 
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Figure 3.8: CLG dose-response curve in vehicle-treated wildtype and PS-1(M146V) 
cortical homogenates. These curves was generated using cortical tissue homogenates 
from wildtype (filled circles) and PS-1(M146V) (open circles) animals. Individual 
homogenates were incubated with increasing concentrations of CLG (in µM) for 20 min 
at room temperature before the assay. Data points represent mean ± SEM (n=4). 
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Part II: Direct interaction between PS-1 and MAO-A proteins in animal and cell 
extracts. 
Results from G.G. Gabriel’s M.Sc. thesis work [134] demonstrated that certain 
AD-related PS-1 variants could affect MAO-A protein and function. The current thesis 
reveals that Ca2+ can alter MAO-A function in an age-dependent manner in the PS-
1(M146V) mouse cortex (Figure 3.1) and that MAO-A protein induction (Figure 3.2) 
does not necessarily result in an increase in MAO-A catalytic activity, thus suggesting a 
post-translational event might be involved. Clearly, the PS-1(M146V) mice respond 
differently to MAO-A inhibition during behavioural test (Figure 3.4) and their 
monoaminergic tone is also affected (Figure 3.5 & 3.6). The change in the potency of 
CLG in the PS-1(M146V) mouse suggests that the MAO-A protein in these mice is 
somehow altered or influenced (Figure 3.7 & 3.8). CLG dose-response curves revealed 
differences in the respective Hill coefficients which suggest a change in cooperativity and 
a change in conformation or access by the substrate to the catalytic pocket.  
At this point, I chose to re-direct my studies to cell culture-based approaches so 
that I could investigate the effect of PS-1(M146V) on MAO-A more closely. 
 
3.8 PS-1(M146V) affects Ca2+-sensitive MAO-A activity in HT-22 cells. 
Therefore, the next series of experiments were focused on in vitro assays. Before 
starting the test using cell cultures, I selected four cell lines to examine their 
overexpression ability as well as endogenous MAO-A/PS-1 level. Among the four 
different cell lines, which are HT-22, HEK, N2a and PC12, HT-22 cells have a high basal 
MAO-A activity while N2a and HEK cells are almost functionally null. As such, I chose 
to use HT-22 cells to examine the effects of drug or overexpressed PS-1 mutant on 
endogenous MAO-A activity and, when necessary, N2a cells for the study of protein 
interaction using overexpressed MAO-A protein(s). 
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Figure 3.9: Overexpression of PS-1 wildtype and PS-1(M146V) affects Ca2+-MAO-A 
activity in HT-22 cells. (A) Basal (veh: 0 mM Ca2+) level of MAO-A activity is not 
significant different between vector-, PS-1 wildtype- and PS-1(M146V)-transfected cells. 
1 mM Ca2+ slightly increased (about 20%) MAO-A activity in vector-transfected cells, 
but this was reduced significantly in PS-1 wildtype- and PS-1(M146V)-transfected cells.  
(B) The expression of PS1 wildtype as well as M146V protein in HT-22 cells was 
verified by western blot. Endogenous MAO-A protein levels are the same in all three 
groups. #: P<0.05 versus vehicle-treated control homogenates, (mean±SEM, n=4-5). 
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Figure 3.9 shows that the PS-1 proteins affects Ca2+-sensitive MAO-A activity in 
HT-22 cells. The cells were transfected with vector, PS-1 wildtype and PS-1(M146V) for 
24 hours. Before the activity assay, homogenates were incubated with 1 mM of Ca2+ (20 
min at room temperature). Neither overexpressed PS-1 protein had any effect on basal 
MAO-A activity [F(2,20)=0.399, P=0.676], but both PS-1 proteins affected the Ca2+-
sensitive component of MAO-A activity observed in the vector-transfected control group 
[F(1,20)=6.860, P=0.016]. Therefore, exogenous PS-1 (either wildtype or the M146V 
variant) both affect MAO-A function.  
 
3.9 Cell viability of PS-1(M146V)-overexpressing HT-22 cells in the absence and 
presence of CLG. 
The PS-1 WT and PS-1(M146V) proteins did not alter MTT conversion, used 
herein as an indicator of mitochondrial integrity and cell viability. Although the selective 
MAO-A inhibitor CLG tended to increase cell viability and although this tended to be 
negated by overexpression of the PS-1 proteins, this did not reach statistical significance 
[F(5,35)=1.934, P=0.1180]  (Figure 3.10). 
 
3.10 MAO-A (endogenous and exogenous) co-immunoprecipitates with PS-1 
proteins in HT-22 cells. 
The literature suggests that PS-1/γ-secretase can be found in the mitochondria [85, 
135] and that the concentration of PS-1 is significantly increased in portions of the 
endoplasmic reticulum membrane that are closest to mitochondria [136]. Furthermore, 
protein-protein interactions between the endoplasmic reticulum and the mitochondria are 
now acknowledged to facilitate inter-organelle communication and metabolic exchange 
between the two organelles [137]. Given that PS-1 is normally expressed on the 
endoplasmic reticulum and that MAO-A is expressed on the mitochondria, I chose to 
examine whether the effects of PS-1 on MAO-A function could be due to a direct 
interaction between the two proteins. I chose to examine this using either the endogenous 
proteins or transiently transfected proteins, i.e. a myc-tagged MAO-A protein and a 
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3XFLAG-tagged PS-1 protein. In the case of the endogenous proteins (MAO-A), I 
overexpressed  untagged PS-1 WT and  PS-1(M146V) (in the  pcDNA3.1  vector).  These 
 
 
 
 
 
 
 
 
 
Figure 3.10: MTT reduction in HT-22 cells overexpressing PS-1 proteins. There was 
no effect of either PS-1 wildtype (WT) or PS-1(M146V) (M/V) either alone or in 
combination with CLG (1 µM, 24 h) on MTT reduction in HT-22 cells (mean±SEM, 
n=4-5). 
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(previous page) 
Figure 3.11: MAO-A co-immunoprecipitates with PS-1 proteins in cell cultures. (A) 
HT-22 cells were transfected with the empty vector (vec) or pcDNA3.1 plasmids coding 
for PS-1 wildtype (WT) and PS-1(M16V) for 24 h. The protein was extracted and PS-1 
was immunoprecipitated. Resolved proteins were probed for endogenous MAO-A. (B) 
HT-22 cells were transfected with the empty FLAG vector (vec) or plasmids coding for 
FLAG-PS-1 wildtype (WT) and FLAG-PS-1(M16V) for 24 h. PS-1 was 
immunoprecipitated with anti-FLAG. Resolved proteins were probed for endogenous 
MAO-A. (C) HT-22 cells were co-transfected with myc-tagged MAO-A and either the 
empty FLAG vector (vec) or plasmids coding for FLAG-PS-1 wildtype (WT) and FLAG-
PS-1(M16V) for 24 h. The vec/vec group was transfected with the myc-vector as well as 
the FLAG-vector and is used as the control group in this experiment. PS-1 was 
immunoprecipitated with anti-FLAG. Resolved proteins were probed with anti-myc 
(MAO-A). MAO-A expression was confirmed by probing for myc and PS-1 expression 
was confirmed by probing for FLAG (revealing the endoproteolytically derived N-
terminal fragment). β-Actin was used to demonstrate that equal amounts of protein were 
loaded in each lane (n=3). IB: Immunoblot/Western blot. IgG: heavy chain of the 
immunoprecipitating IgG antibody. 
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proteins were immunoprecipitated using an antibody that was directed towards the loop 
region of PS-1. The SDS-PAGE resolved proteins were then probed for endogenous 
MAO-A using the H-70 antibody. MAO-A was detected, albeit very weakly, in both 
extracts from cultures overexpressing PS-1 proteins (Figure 3.11A). The experiment was 
repeated, but this time FLAG-tagged PS-1 proteins were overexpressed. MAO-A was 
again detected in FLAG-immunoprecipitates (Figure 3.11B), but still the detection of 
MAO-A was relatively weak. A final experiment was performed in which both PS-1 
(FLAG-tagged) and MAO-A were overexpressed (Figure 3.11C). In this case, MAO-A 
expression (detected using the myc antibody) was obvious and was only 
immunoprecipitated from extracts in which PS-1 WT and PS-1(M146V) were 
overexpressed. These data strongly support a physical association between PS-1 proteins 
and MAO-A in HT-22 cells.   
 
3.11 DAPT increases MAO-A activity in HT-22 cells and PS-1(M146V) knock-in 
mice. 
As the possibility that MAO-A protein could be interacting with PS-1 proteins in 
a non-specific or non-functional manner cannot be fully excluded by co-
immunoprecipitation experiments, I chose to use another approach to support my 
hypothesis that PS-1 and MAO-A interact on a functional level. Since MAO-A function 
is inhibited by expression of PS-1(M146V) (current thesis; corroborates work done by a 
previous M.Sc. student in our group [134]), I chose to use a PS-1 inhibitor to determine 
whether it could influence MAO-A catalytic activity (given the potential for close 
proximity between the two proteins). I chose to use the semi-peptidic N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) as it was the first γ-
secretase inhibitor to have been studied in vitro [138] and is now known to act as a 
substrate-inhibitor for γ-secretase function  [139].  
Overexpression of PS-1 proteins tended to increase MAO-A activity 
[F(5,17)=5.945, P=0.005], although post hoc analysis indicated that this was not 
significant. In contrast, parallel homogenates incubated with DAPT clearly had 
significantly enhanced MAO-A activity (Figure 3.12). This supports the observation  that  
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Figure 3.12: Treatment of PS-1/γ-secretase inhibitor DAPT increases MAO-A 
activity in HT-22 cells. HT-22 cell homogenates, from cultures that overexpressed either 
PS-1 wildtype (WT) or the PS-1(M146V) (M/V) protein, were incubated with the PS-1/γ-
secretase inhibitor DAPT at concentration of 1 µM. The endogenous MAO-A activity 
(herein indicated as the activity measured in vehicle (VEH)-treated, vector (vec)-
transfected HT-22 cultures) was determined. Compared with the VEH-treated cells, 
MAO-A activity was not significantly affected by overexpression of either PS-1 WT or 
PS-1(M146V) proteins alone, but was significantly increased when the corresponding 
homogenates were treated with DAPT. n.s. = not significant; *: P<0.05 & **: P<0.01 
versus vehicle or between indicated groups, (mean±SEM, n=4-7). 
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DAPT also can enhance MAO-A activity in PS-1(M146V) mouse extracts [134]. The use 
of frozen tissues and incubation of the  homogenates with  DAPT precludes any events  
atthe transcriptional and translational levels. Therefore, PS-1 must interact with MAO-A 
in vivo.  
 
3.12 CLG promotes the interaction between PS-1 and MAO. 
Since incubation of a homogenate with DAPT can increase MAO-A activity, and 
thus suggests an interaction between PS-1 and MAO-A in vivo, I chose to examine 
whether the PS-1 protein and the MAO-A protein could be co-immunoprecipitated from 
mouse cortical extracts. Pre-cleared extracts were immunoprecipitated with the PS-1 loop 
antibody and the SDS-PAGE resolved proteins were probed for MAO-A. Both wildtype 
PS-1 and PS-1(M146V) were found to co-immunoprecipitate MAO-A (Figure 3.13). At 
the same time, extracts from CLG-treated mice were also examined. It was noticed that in 
extracts from these CLG-treated mice the co-immunoprecipitation was enhanced. The 
middle panel of Figure 3.13 reveals that in pre-cleared tissue lysates, two MAO-A bands 
were detected and that one of these bands (at ~45 kDa) disappeared with CLG treatment. 
This suggests the possibility that MAO-A could normally be cleaved and that CLG 
somehow interferes with this process. The process could be a PS-1-dependent 
mechanism. The physiological relevance of this remains unclear. 
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Figure 3.13: Immunoprecipitation assay for PS-1 and MAO-A in CLG treated/non-
CLG-treated PS-1 wildtype or PS-1(M146V) mouse cortex. PS-1 was 
immunoprecipitated (anti-loop) from cortical extracts and resolved proteins were probed 
for MAO-A. These preliminary results reveal that in CLG-treated animals, PS-1 
interacted more with MAO-A protein (top panel). At the same time, a 46 kDa band was 
lost in these two sample detected by immune blot (IB) (middle panel).  
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Part III: Mapping the potential motif for interaction between PS-1 and MAO-A 
The above preliminary data suggest that PS-1 could be mediating a MAO-A 
cleavage event. Alignment of the primary amino acid sequence of MAO-A and MAO-B 
confirms the high sequence identity between these two proteins, and when aligned with 
APP (substrate for PS-1/γ-secretase cleavage), it becomes apparent that there is some 
sequence identity in the region highlighted in Figure 3.14. Furthermore, both MAO-A 
and MAO-B contain a motif that is very similar to the “GVVIA” motif that is targeted by 
PS-1/γ-secretase to release the Aβ(1-40) and Aβ(1-42) peptides that are thought to be 
central to AD-related pathology. Cleavage of APP after “GVV” releases the Aβ(1-40) 
fragment; cleavage after the “VIA” releases the Aβ(1-42) fragment. Since there is only 
one amino acid different within this motif between MAO-A and MAO-B, we have 
mutated the “A” (alanine) to “S” (serine) in the MAO-A protein; this strategy gives an 
MAO-A protein that contains the MAO-B “GSVIK” motif. The same strategy was used 
to mutate the MAO-B protein such that it now contains the MAO-A “GAVIK” motif. 
Note that the Alanine residue in MAO-A is residue 302, whereas the corresponding 
residue in MAO-B, i.e. the serine, is residue 293. I chose to determine whether these 
substitutions would affect the function of either MAO-A or MAO-B. 
 
 3.13 Chromatogram sequences of MAO-A A302S and MAO-B S293A. 
The mutation in MAO-A (to give the A302S substitution) was confirmed by DNA 
sequencing (Figure 3.15). The mutation in MAO-B (to give the S293A substitution) was 
also confirmed by DNA sequencing (Figure 3.15). The gene mutation was achieved using 
Stratagene’s QuikChange® Site-Directed Mutagenesis Kit. 
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Figure 3.14: MAO-A contains a putative PS-1 binding site. Alignment of the MAO-A 
and MAO-B primary amino acid sequences not only confirm their high sequence identity, 
but also reveals that both MAO-A and MAO-B contain a motif “GA/SVIK” that is very 
similar to the “GVVIA” motif in APP that is targeted for cleavage by PS-1/γ-secretase. 
Cleavage of APP after “GVV” releases the Aβ(1-40) fragment; cleavage after the “VIA” 
releases the Aβ(1-42) fragment. The highlighted “KKK” is the recognized highly charged 
portion (anchor) of the transmembrane domain of the APP protein. 
  
59 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Sequencing of targeted codon substitutions in MAO-A and MAO-B. 
(left) Chromatograms show the mutated codon in MAO-A (TCT=Serine, S) and (right) 
the corresponding mutated codon in MAO-B (GCA=Alanine, A). The wildtype codons 
GCT (=Alanine, A) in MAO-A and TCA (=Serine, S) in MAO-B are indicated 
immediately above the mutated ones. 
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3.14 Molecular evidence of the PS-1 targeting motif in MAO-A. 
MAO-A(A302S) and MAO-B(S293A) and the corresponding wildtype proteins 
were overexpressed in N2a cells for 24 hours (Figure 3.16A,B). N2a cells were used for 
this study as they are functionally MAO-A null [128] and are therefore a good model to 
test the activity of overexpressed MAO-A proteins. Immuno/Western blot confirmed the 
expression and revealed that the single amino acid substitution did not affect expression 
levels of the respective proteins. Assaying for catalytic activity reveals that the A-to-S 
substitution increases MAO-A activity by approximately 25% (Figure 3.16C), but also 
interferes with the interaction between PS-1 and MAO-A (Figure 3.16E). MAO-B 
activity (estimated using [14C-phenylethylamine] as substrate) reveals that the S-to-A 
substitution in MAO-B results in a decrease of approximately 50% (Figure 3.16D).  
 
3.15 MAO-A activity in HT-22 cultures is increased by expression of depression-
related PS-1 mutants. 
Wildtype PS-1 and the PS-1(A431E) and PS-1(L235V) variants that have been 
associated with an increase in the incidence of depression in pre-demented patients [2] 
were overexpressed in HT-22 cells for 24 hours (Figure 3.17). These proteins exerted an 
effect on endogenous MAO-A activity [F(3,22)=3.985, P=0.0233]. MAO-A activity was 
increased by the PS-1(A431E) protein (Figure 3.17), thus suggesting that this mutant may 
play a direct role in the aminergic dysregulation associated with depression in the carriers 
of this mutation. In contrast, while overexpression of the PS-1(L285V) protein did exert a 
minor effect on MAO-A activity, this was clearly not significant. This suggests that 
different PS-1 mutants could exert distinct effects on MAO-A in vivo and hence employ 
distinct mechanisms to induce depression in the carriers of the respective mutations.  
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Figure 3.16: Molecular evidence of a putative PS-1 targeting motif in MAO-A. (A) 
MAO-A(A302S) and (B) MAO-B(S293A) and the corresponding wildtype (WT) proteins 
were overexpressed in N2a cells for 24 hours. Immunoblot (IB) demonstrated that the 
substitution does not affect protein expression. (C) MAO-A activity was enhanced by 
substitution of “A” to “S” while (D) MAO-B activity was decreased substitution of “S” to 
“A”. (E) The co-immunoprecipitation between PS-1 and MAO-A in N2a cells is 
diminished in cells overexpressing MAO-A(A302S) compared to MAO-A wildtype. *: 
P<0.05 and ***: P<0.001, versus the corresponding WT-transfected (mean±SEM, n=3). 
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Figure 3.17: MAO-A activity is increased by overexpression of a depression-related 
PS-1 mutant. The vector, PS-1 wildtype, and two PS-1 variants [PS-1(A431E), A/E; PS-
1(L235V), L/V) were transfected into HT-22 cell line for 24 hours. The immunoblot (IB) 
confirms the overexpression of the FLAG-tagged PS-1 proteins (FL: full length; NTF: N-
terminal fragment). Levels of β-Actin demonstrate equal protein loading in all four lanes. 
The endogenous MAO-A activity was then measured. MAO-A activity of cells 
overexpressing PS-1(A431E) was increased approximately 50%, while the activity in 
cells overexpressing PS-1(L235V) did not change compared with cells overexpressing 
the PS-1 wildtype (WT) protein. n.s.: non-specific band. . *: P<0.05 versus vector 
(VEC)-transfected (mean±SEM, n=9-10). 
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4. Discussion. 
As early as 1996, early mood changes, including depression, had been found to be 
a common symptom in AD patients [2]. Neurochemical changes, particularly with 
monoamines such as serotonin and noradrenaline, have long been associated with some 
of the earliest events in AD [60]. AD is a multi-factorial disease, which includes 
influences by genetics, cerebrovascular disease and age, and unfortunately the clinical 
symptoms of the disease usually present 20-30 years after the onset of pathological 
changes. Therefore, AD is still a not curable neurodegenerative disease due to the lack of 
a targetable system. However, discovery of the link between a history of depression and 
AD possibly suggests a common mechanism, especially one that occurs at an early stage 
of the development of the disease. The main substrate of MAO-A, i.e. serotonin/5-HT, is 
implicated in major depression [17]. MAO-A is also thought to contribute to oxidative 
stress through the production of hydrogen peroxide as a natural by-product of the 
degradation of monoamines. With this in mind, perhaps it is not surprising that some of 
the most vulnerable cells in the AD brain are cells that are highly immunoreactive for 
MAO-A  [29]. This thesis work was an extension of the work previously undertaken by a 
Master’s student in our laboratory [134]. Since people with a history of depression tend 
to be at higher risk for developing AD and that certain PS-1 mutants are reportedly 
associated with an increase in depression [2], I hypothesized that PS-1 mutants could 
contribute to changes in biogenic amine function at early stages of the disease. These 
changes could not only lead to depression, but ultimately could lead to neurotoxicity 
(increased MAO-A-mediated oxidative stress) and AD.  
PS-1 is the catalytic core of the γ-secretase complex, which plays an important 
role in the APP cleavage process and produces β-amyloid protein (Aβ). Since Aβ 
accumulation is thought to be a key step in the pathogenesis of AD, most of the literature 
focuses more on the APP/PS-1 double transgenic mouse models that have an exaggerated 
Aβ burden because of the expression of the two mutant proteins. However, Aβ is usually 
produced in the late stage of AD, well after neurochemical changes and 
neurodegeneration. In these animal models, monoamine levels change [140, 141]. While 
these monoamines, e.g. serotonin and norepinephrine (NE), are known substrates of 
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MAO-A, it is surprising that the function of MAO-A in these animals has never been 
examined (or perhaps simply not reported). I used the commercially available PS-
1(M146V) knock-in mice to do the current thesis work as it provides a nice platform to 
investigate how an AD-related PS-1 protein could (on its own) affect MAO-A function.  
In order to determine if wildtype PS-1 animals are different from the PS-
1(M146V) knock-in littermates, cortical and cerebellar tissues were assayed for MAO-A 
activity. As the literature suggests that the PS-1(M146V) mutation can induce a 
significant disruption of Ca2+ homeostasis [142-144], both basal and Ca2+-sensitive 
MAO-A activity [128, 129] was examined. In the PS-1(M146V) mice, basal cortical 
MAO-A activity was increased by approximately 10% while the Ca2+-sensitive 
component to MAO-A activity was increased approximately 30%. Moreover, this 
increasing Ca2+-sensitivity of MAO-A occurred in an age- and region-dependent manner 
(i.e. no changes were observed in cerebellum). Interestingly, when we looked at the level 
of expression of the MAO-A protein, there was approximately 50% more MAO-A 
protein when compared to MAO-A expression in wildtype mice. The mismatch between 
MAO-A protein and activity suggested the possibility of some posttranslational event(s) 
regulating MAO-A function. Whether this is occurring while MAO-A is expressed within 
the mitochondria or whether this is occurring when MAO-A is being processed through 
the endoplasmic reticulum and golgi apparatus is unclear. The presence of an active 
overexpressed MAO-A protein in these cells suggested that MAO-A is expressed on the 
mitochondria. This, then, suggested that the effect of PS-1 is between organelles. 
The disturbed laminar architecture in the PS-1(M146V) mouse cortex, in 
comparison to the wildtype animal, is another example of subtle effects of this transgene 
on the central nervous system. The PS-1 protein is not simply involved in the 
neuropathology that accompanies AD [145], but is also required for the normal 
development of the cerebral cortex [146, 147]. The patchy distribution of Nissl substance 
and disrupted laminar boundaries in the cortices of PS-1(M146V) mice was consistent 
with reports using prenatal PS-1-null mice [148] and postnatal PS-1 conditional knockout 
mice [147]; a priori, if PS-1(M146V) is inhibiting MAO-A, as the current activity data 
indicate, then a role for a PS-1(M146V)-mediated inhibition of MAO-A in laminar 
disorganization is possible. This is supported indirectly by the cytoarchitectural changes 
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observed in the cortex of MAO-A-knockout mice [44] and following MAO-A inhibition 
and hyperserotoninergic (but not noradrenergic) function during the first week of life in 
wildtype  mice [149]. 
To study if MAO-A-dependent behaviour correlated with the expression of the 
PS-1(M146V) protein, the mice were subjected to the forced swim test (a test of non-
cognitive behaviours in rodents). The PS-1 transgene did not cause any behavioural 
phenotype on its own. However when the mice were treated with the selective MAO-A 
inhibitor CLG, a significant decrease of the time that the PS-1(M146V) mice spent 
swimming was observed. The fact that CLG treatment increased the duration of 
immobility in the forced swim test, rather than decreasing it (which would be the typical 
profile of an “antidepressant” drug) was somewhat unexpected, but this did support 
reports that MAO inhibitors do not consistently give a “positive” result in this test 
[reviewed in [150]]. Combining this with the region- and age-dependent activity change, 
as well as change of protein distribution, it would be reasonable to assume that PS-
1(M146V) transgene does affect MAO-A function in these animals to a certain extent and 
would therefore affect the level of neurochemistry of the brain, especially aminergic 
substrates. Indeed, HPLC analysis of monoamines and selected metabolites demonstrated 
a significant decrease in cortical levels of 5-HIAA (an MAO-A-mediated metabolite of 5-
HT). The decreased levels of 5-HIAA were not due to a lower 5-HT synthesis or its 
precursor trytophan because a parallel increase in levels of 5-HT was observed. This 
supported the notion that MAO-A function was inhibited in a PS-1(M146V) background. 
Cognitive dysfunction is characteristic of the later stages of clinical AD. Yet 
earlier stages of AD are associated more often with several non-cognitive symptoms 
including depression [151]. Given that depression does respond to MAO-A inhibition and 
that depression is associated with region-specific noradrenergic and serotoninergic 
etiologies, it is not surprising that acute CLG treatment would affect both noradrenergic 
and serotoninergic metabolism in the PS-1(M146V) mice. The fact that noradrenergic 
changes were not only region-dependent, but also were greater than serotoninergic 
changes, is also not unexpected [152, 153]. Indeed, acute CLG treatment is known to 
elicit some off-target effects on the noradrenergic synthetic enzyme, tyrosine hydroxylase 
[154]. Exacerbated changes in noradrenergic and serotoninergic metabolism following 
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acute CLG treatment in PS-1(M146V) mice could certainly contribute to the changes in 
non-cognitive symptoms (defined herein by the forced-swim test). 
 Mutation-induced changes in the conformation of the PS-1 protein are known to 
exist [155]. Perhaps by virtue of a direct association between PS-1(M146V) and MAO-A, 
a change in the structure of MAO-A could ensue and this could explain the increased 
potency of CLG in the PS-1(M146V) mouse cortical and cerebellar samples. A 
conformational change in the MAO-A protein could certainly alter the accessibility of 
CLG to its binding site, which could promote an apparent change in the Hill slope 
without significantly shifting the IC50 for CLG towards MAO-A. While this suggests 
partially interconvertible states of a single CLG binding site, it could also be indicating a 
PS-1-dependent post-translational mechanism. In support of the latter possibility, PS-1 
variants are known to activate distinct signalling cascades [156], several of which have 
been found by our research group to affect MAO-A function [128]. 
The potential for post-translational modification also suggests the possibility for a 
direct influence of the PS-1 protein on MAO-A function. At this point, I chose to 
continue characterizing the influence of PS-1 on MAO-A using overexpression strategies 
in cell cultures. 
The data collected from the mice suggested significant differences between PS-1 
wildtype and PS-1(M146V) proteins in terms of their effect(s) on MAO-A function. In 
the immortalized neuronal HT-22 cell line, the overexpression of both PS-1 wildtype and 
PS-1(M146V) proteins diminished the Ca2+-sensitive component to MAO-A activity. The 
reason for the different tendencies in cell cultures versus animal tissue could be due to the 
transient expression (in cell cultures) compared with six months of expression in the PS-
1(M146V) mice. Furthermore, the cell culture is clonal (i.e. one cell type), whereas the 
results from the tissues represent the average response of all cell types in that tissue. The 
toxicity of PS-1 mutants was also determined using MTT conversion as an indirect 
indicator of cell viability. A decrease in viability of cells overexpressing either PS-1 
wildtype or the PS-1(M146V) proteins was observed, but only the PS-1(M146V)-induced 
effect was sensitive to inhibition of MAO-A. Although the reason for the differences 
remains unclear, what can be concluded from the cell-based assays is that PS-1 proteins 
can exert MAO-A-sensitive effects in vitro. The observation that the MAO-A protein 
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could be co-immunoprecipitated by PS-1 was strong evidence that the effect of PS-1 
proteins could be due to a direct association between the two proteins. Although this was 
initially unexpected, the literature does support the possibility that proteins expressed on 
the endoplasmic reticulum can interact directly with mitochondrial proteins [137]. The 
possibility that PS-1 could be similarly influencing mitochondrial proteins is supported 
by several lines of evidence including (a) the concentration of PS-1 proteins in the 
endoplasmic reticulum membranes that are closest to the mitochondria [136] and (b) the 
detection of PS-1 and other components of the γ-secretase complex in the mitochondrial 
fraction [85, 135]. A direct association between PS-1 proteins and MAO-A was further 
supported by the ability of the γ-secretase substrate-competitor DAPT [139] to increase 
MAO-A activity in both cell cultures (current thesis) and PS-1(M146V) mouse cortical 
homogenates [134]. This appeared to suggest that DAPT, by binding with the C-terminal 
of PS-1, is blocking the access of substrate to MAO-A. When MAO-A is no longer 
associated with PS-1/γ-secretase because of competition by DAPT, then MAO-A activity 
is enhanced. This indirectly confirmed that PS-1(M146V) inhibits MAO-A activity in 
vivo (which is the conclusion drawn from the mismatch between MAO-A protein and 
MAO-A activity in the PS-1(M146V) cortical homogenates). 
A previous Master’s thesis from this laboratory [134] demonstrated that 
overexpression of the AD-associated PS-1 mutants, such as the highly aggressive PS-
1(Y115H) protein, can lead to the cleavage of MAO-A to form a C-terminal fragment 
[134]. If it is true, then MAO-A could be a novel substrate for PS-1/γ-secretase. Based on 
alignments of MAO-A and MAO-B (and the well-known substrate APP), a putative PS-1 
binding/cleavage site was identified. As MAO-B does not appear to associate as readily 
with PS-1 [134] and this putative cleavage site in MAO-A and MAO-B differs by a 
single amino acid, substitution mutants were generated such that MAO-A contained the 
MAO-B-specific amino acid (and MAO-B contained the MAO-A-specific amino acid). 
In keeping with PS-1 possibly inhibiting MAO-A function, the A-to-S substitution in 
MAO-A not only increased the catalytic activity of the overexpressed MAO-A protein, 
but this protein also interacted less with PS-1 (determined by co-immunoprecipitation 
experiments). In contrast, the complementary substitution in MAO-B decreased the 
catalytic activity of the overexpressed MAO-B protein. Work in the laboratory is 
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currently underway to determine whether this substitution affects the ability of MAO-B 
to interact with PS-1 protein(s). 
Mutated forms of PS-1 have been associated with particularly aggressive forms of 
AD. The fact that some of these mutations have also been associated with depression in 
pre-demented AD patients is very exciting. This suggests that depression and AD might 
share a common causative biochemical mechanism. The evidence provided herein 
supports a role for PS-1 proteins in MAO-A function both in vivo and in vitro. It is worth 
noting that different forms of PS-1 mutant may cause very different effects on MAO-A 
function. Obviously, the PS-1(M146V) protein inhibited MAO-A. The PS-1(A431E) 
protein (but a priori not the PS-1(L285V) protein), both of which have been reported to 
induce a clinical depression phenotype [2], activated MAO-A. This needs to be examined 
more closely, but differences in the effects of PS-1 variants on cellular mechanisms and 
phenotypes are well documented and a direct role for some of these variants in depression 
is certainly feasible, although multiple mechanisms of actions might be involved (direct 
and/or indirect), including mechanisms dependent on MAO-A dysfunction. Further 
examination of this interesting and unique endogenous means of regulating MAO-A 
function, as well as its relation to clinically relevant pathologies, including depression 
and AD, is clearly warranted. 
 
5. Future Directions 
The current study has demonstrated an endogenous mechanism of regulating 
MAO-A function by PS-1 proteins. As a binding partner of γ-secretase, a potential 
binding motif of MAO-A was also studied in this thesis. However some further 
experiments are still needed to prove the interaction between the two proteins. First, the 
co-localization of PS-1 and MAO-A in AD/depression-related brain has not been fully 
established. Therefore, it would be important to monitor the subcellular localization of 
the two proteins, not only to determine where they are expressed, but also if they affect 
each other’s processing and/or transport. Second, a potential MAO-A C-terminal 
cleavage product was observed both in vivo and in vitro by immunoblot. As such, further 
studies are needed to confirm that these detected bands indeed represent smaller MAO-A 
species or fragments. The putative binding site in MAO-A identified in this thesis project 
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could be helpful to examine this potential cleavage process. Third, the potential change of 
conformation in MAO-A, as suggested by the increased potency of CLG in the PS-
1(M146V) mice, needs to be examined as it would be important to understand how 
MAO-A structure could be affected by binding with PS-1. This would also be very useful 
in characterizing the binding parameters needed for the association between PS-1 and 
MAO-A. Fourth, we noticed that in PS-1(M146V) knock-in mice, there was a significant 
increase in MAO-A protein, but that there was no corresponding change in MAO-A 
activity. Further understanding of the mechanism underlying the mismatch between 
protein and function would be important, as would its contribution to MAO-A protein 
turnover in the AD-related mouse and, ultimately, in the human condition. Finally, our 
data also suggested that different PS-1 mutants might be eliciting different effects on 
MAO-A function. Therefore, more animal models expressing PS-1 mutant proteins, 
especially the highly aggressive (and commercially available) PS-1(ΔEx9) variant, should 
also be examined. 
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